Author: "Tomohisa Iinuma" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Tomohisa Iinuma"' showing total 76 results

Start Over Author "Tomohisa Iinuma"

76 results on '"Tomohisa Iinuma"'

1. Factors contributing to the diagnosis and onset prediction of perennial allergic rhinitis in high-risk children: A sub-analysis of the CHIBA study

Author: Syuji Yonekura, Yoshitaka Okamoto, Fumiya Yamaide, Taiji Nakano, Kiyomi Hirano, Urara Funakoshi, Sawako Hamasaki, Tomohisa Iinuma, Toyoyuki Hanazawa, and Naoki Shimojo
Subjects: Allergies, House dust mite, Nasal eosinophils, Perennial allergic rhinitis, Sensitization, Immunologic diseases. Allergy, RC581-607
Abstract: Background: This study aimed to clarify the diagnostic and predictive factors for perennial allergic rhinitis (PAR) onset in children by analyzing the results of the Chiba High-risk Birth Cohort for Allergy study, which examined newborns with a family history of allergies. Methods: Overall, 306 pregnant women were recruited. Their newborns were examined by otolaryngologists and pediatric allergists at 1, 2, and 5 years of age. Participants with clinical and laboratory data available at all consultation points were considered eligible. Results: Among 187 eligible participants, the prevalence rates of PAR were 2.1%, 4.3%, and 24.1% at 1, 2, and 5 years of age, respectively. AR-specific nasal local findings and eosinophils in nasal smear were observed in a substantial number of patients with PAR at 1 and 2 years of age. Factors present up to 2 years of age that were associated with PAR onset at 5 years of age, in descending order, were as follows: sensitization to house dust mites (HDM), nasal eosinophilia, and sensitization to cat dander. In 44 cases with HDM sensitization, nasal eosinophilia up to 2 years of age achieved a sensitivity of 76.0% and a specificity of 73.7% for predicting PAR onset at 5 years. Conclusions: Rhinitis findings and nasal eosinophilia are useful auxiliary diagnostic items for pediatric PAR. Sensitization to HDM and nasal eosinophilia were the most influential factors associated with future PAR onset. A combination of these factors may facilitate the prediction of PAR onset.
Published: 2024
Full Text: View/download PDF

2. Single-cell RNA sequencing of submandibular gland reveals collagen type XV-positive fibroblasts as a disease-characterizing cell population of IgG4-related disease

Author: Shigeru Tanaka, Takuya Yamamoto, Arifumi Iwata, Masahiro Kiuchi, Kota Kokubo, Tomohisa Iinuma, Takahiro Sugiyama, Toyoyuki Hanazawa, Kiyoshi Hirahara, Kei Ikeda, and Hiroshi Nakajima
Subjects: IgG4-related disease, Fibroblasts, Collagen type XV, Single-cell RNA sequence, Diseases of the musculoskeletal system, RC925-935
Abstract: Abstract Objectives IgG4-related disease (IgG4-RD) is a systemic autoimmune disease with an unknown etiology, affecting single/multiple organ(s). Pathological findings include the infiltration of IgG4-producing plasma cells, obliterative phlebitis, and storiform fibrosis. Although immunological studies have shed light on the dysregulation of lymphocytes in IgG4-RD pathogenesis, the role of non-immune cells remains unclear. This study aimed to investigate the demographics and characteristics of non-immune cells in IgG4-RD and explore potential biomarkers derived from non-immune cells in the sera. Methods We conducted single-cell RNA sequence (scRNA-seq) on non-immune cells isolated from submandibular glands of IgG4-RD patients. We focused on fibroblasts expressing collagen type XV and confirmed the presence of those fibroblasts using immunohistochemistry. Additionally, we measured the levels of collagen type XV in the sera of IgG4-RD patients. Results The scRNA-seq analysis revealed several distinct clusters consisting of fibroblasts, endothelial cells, ductal cells, and muscle cells. Differential gene expression analysis showed upregulation of COL15A1 in IgG4-RD fibroblasts compared to control subjects. Notably, COL15A1-positive fibroblasts exhibited a distinct transcriptome compared to COL15A1-negative counterparts. Immunohistochemical analysis confirmed a significant presence of collagen type XV-positive fibroblasts in IgG4-RD patients. Furthermore, immune-suppressive therapy in active IgG4-RD patients resulted in decreased serum levels of collagen type XV. Conclusions Our findings suggest that collagen type XV-producing fibroblasts may represent a disease-characterizing non-immune cell population in IgG4-RD and hold potential as a disease-monitoring marker.
Published: 2024
Full Text: View/download PDF

3. Nasal septum lesions causing diagnostic difficulty: Case report

Author: Aiko Kishino, Syuji Yonekura, Ichiro Fukumoto, Tomoyuki Arai, Tomohisa Iinuma, Takeshi Suzuki, Kazuki Yamasaki, Yuichiro Otsuka, Manayu Shiina, Masayuki Ota, Jun-ichiro Ikeda, and Toyoyuki Hanazawa
Subjects: Eosinophilic angiocentric fibrosis, benign nasal septal tumors, Rosai-Dorfman disease, IgG4-related disease, Otorhinolaryngology, RF1-547, Surgery, RD1-811
Abstract: AbstractBenign nasal septal tumors are rare and exhibit various histologic features. It is necessary to treat them based on a plan that considers the prognosis, functionality, and esthetics. We report two similar and rare cases of nasal septal tumors with different diagnoses that we treated with nasal septal tumor resection. Eosinophilic angiocentric disease was the most likely diagnosis of one of the two cases, but it was not confirmed by the IgG4:IgG ratio. The other case was diagnosed as extranodal Rosai-Dorfman disease based on its histological features. The histological appearance of nasal septal tumors varies widely; therefore, a careful diagnosis based on both clinical and pathological perspectives is required.
Published: 2023
Full Text: View/download PDF

4. Differences in the expression of multidrug resistance proteins in chronic rhinosinusitis according to endotype

Author: Tomohisa Iinuma, Syuji Yonekura, Kiyoshi Hirahara, Junya Kurita, Riyo Yoneda, Tomoyuki Arai, Yuri Sonobe, Rie Shinmi, Yoshitaka Okamoto, and Toyoyuki Hanazawa
Subjects: Chronic rhinosinusitis, Eosinophils, Gene ontology analysis, Multidrug resistance protein, Multiomics, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Chronic rhinosinusitis is a common disease of the nasal cavity and is classified into two major endotypes, which are neutrophilic and eosinophilic. Some patients with neutrophilic and eosinophilic chronic rhinosinusitis are refractory to treatment, and the mechanism of drug resistance is not completely understood. Methods: Nasal polyp samples were collected from patients with non-eosinophilic chronic rhinosinusitis (nECRS) and eosinophilic chronic rhinosinusitis (ECRS). Transcriptomic and proteomic analyses were performed simultaneously. Gene Ontology (GO) analysis was conducted to extract genes involved in drug resistance. Then, GO analysis results were validated via real-time polymerase chain reaction and immunohistochemistry analysis. Results: The nasal polyps of patients with ECRS were enriched with 110 factors in the genes and 112 in the proteins, unlike in those of patients with nECRS. GO analysis on the combined results of both showed that the factors involved in extracellular transportation were enriched. Our analysis focused on multidrug resistance protein 1–5 (MRP1–5). Real-time polymerase chain reaction revealed that the MRP4 expression was significantly upregulated in ECRS polyps. Immunohistochemical staining showed that the MRP3 and MRP4 expressions significantly increased in nECRS and ECRS, respectively. MRP3 and MRP4 expressions were positively correlated with the number of neutrophil and eosinophil infiltrates in polyps and associated with the tendency to relapse in patients with ECRS. Conclusions: MRP is associated with treatment resistance and is expressed in nasal polyps. The expression pattern had different features based on chronic rhinosinusitis endotype. Therefore, drug resistance factors can be associated with therapeutic outcomes.
Published: 2023
Full Text: View/download PDF

5. Characterization of eosinophils and natural killer cells in nasal polyps and peripheral blood in eosinophilic chronic rhinosinusitis patients

Author: Kaori Tsuji, Ami Aoki, Atsushi Onodera, Masahiro Kiuchi, Kota Kokubo, Yuki Morimoto, Tomohisa Iinuma, Toyoyuki Hanazawa, Toshinori Nakayama, and Kiyoshi Hirahara
Subjects: Immunologic diseases. Allergy, RC581-607
Published: 2023
Full Text: View/download PDF

6. Preoperative simulation using three‐dimensional printer in four temporal bone surgeries

Author: Ichiro Fukumoto, Yukiyoshi Mita, Rie Shimmi, Yuri Sonobe, Tomohisa Iinuma, Kazuki Yamasaki, Shuji Yonekura, Toshimitsu Nemoto, and Toyoyuki Hanazawa
Subjects: otology, preoperative simulation, temporal bone surgery, three‐dimensional printer, Medicine, Medicine (General), R5-920
Abstract: Abstract Preoperative simulation using a three‐dimensional printer is effective to perform safe surgery by knowing the range limit of drilling in the temporal bone. Moreover, simulations using models are thought to be useful for education of young surgeon.
Published: 2023
Full Text: View/download PDF

7. Characteristics of Japanese cypress pollen-induced allergic rhinitis by environmental challenge chamber

Author: Minami Koriyama, Yoshitaka Okamoto, Takeshi Suzuki, Tomohisa Iinuma, Heizaburou Yamamoto, Yusuke Okuma, Sawako Hamasaki, Daiju Sakurai, Toyoyuki Hanazawa, and Syuji Yonekura
Subjects: Immunologic diseases. Allergy, RC581-607
Published: 2022
Full Text: View/download PDF

8. Evaluation of shoseiryuto for seasonal allergic rhinitis, using an environmental challenge chamber

Author: Junya Kurita, MD, PhD, Syuji Yonekura, MD, PhD, Tomohisa Iinuma, MD, PhD, Riyo Yoneda, MD, PhD, Sakiko Imamoto, MD, PhD, Toyoyuki Hanazawa, MD, PhD, Yohei Kawasaki, PhD, Takao Namiki, MD, PhD, and Yoshitaka Okamoto, MD, PhD
Subjects: Allergic rhinitis, Cedar pollen, Environmental challenge chamber, Randomized placebo-controlled crossover double-blind study, Shoseiryuto, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Complementary and alternative medicine, including Japanese traditional medicine (JTM), has been used for various allergic diseases, but the evidence is limited. Shoseiryuto (Xiao-Qing-Long-Tang), one of the representative JTM drugs, is frequently used to treat allergic rhinitis (AR). However, its efficacy for seasonal AR has not been fully established. Using an Environmental challenge chamber (ECC), we evaluated the therapeutic effects of shoseiryuto on AR induced by Japanese cedar pollen (JCP). Methods: A placebo-controlled double-blind crossover study with shoseiryuto was conducted using the ECC. The shoseiryuto or placebo was orally administered from 2 weeks before the exposure test. The pollen exposure test was conducted for 3 h, and the pollen concentration was set at 8000 pollen/m3. The primary endpoint of the study was the total nasal symptom score (TNSS) during pollen exposure. A physician certified by the Japanese Society of Oriental Medicine as a specialist checked each participant's “pattern”, a comprehensive expression of signs obtained from individual patients' subjective symptoms and other personal findings. Blood samples collected just before the first pollen exposure were stimulated with cedar antigens and used for immunological studies. Results: The results of the 46 participants were analyzed, and no significant side effects were detected. There was no significant difference in TNSS during pollen exposure for 3 h in the ECC between the shoseiryuto and placebo groups. However, some symptoms were improved in the shoseiryuto group after leaving the ECC. There was no significant correlation between the “fluid retention pattern” and TNSS. In immunological studies, shoseiryuto did not inhibit Th2-type cytokine production and mRNA expression. Conclusions: Oral administration of shoseiryuto from 2 weeks before pollen exposure did not prevent or inhibit immediate symptoms of AR induced by JCP in the ECC. Further study is needed to reevaluate the shoseiryuto specific “pattern” in JTM.
Published: 2022
Full Text: View/download PDF

9. A case of jugular bulb diverticulum causing pulsatile tinnitus

Author: Ichiro Fukumoto, Kazuki Yamasaki, Shuji Yonekura, Tomohisa Iinuma, Yukiyoshi Mita, Yuri Sonobe, and Toyoyuki Hanazawa
Subjects: high jugular bulb, jugular bulb diverticulum, pulsatile tinnitus, Medicine, Medicine (General), R5-920
Abstract: Abstract If you suspect pulsatile tinnitus from a medical interview, you should check for jugular bulb diverticulum and cortical bone defects on temporal bone CT, in addition to thorough physical examination and contrast‐enhanced imaging.
Published: 2021
Full Text: View/download PDF

10. Complement Factor H Is an Early Predictive Biomarker of the Therapeutic Efficacy of Sublingual Immunotherapy for Japanese Cedar Pollinosis

Author: Riyo Yoneda, Tomohisa Iinuma, Daiju Sakurai, Junya Kurita, Tomoyuki Arai, Yuri Sonobe, Syuji Yonekura, Yoshitaka Okamoto, and Toyoyuki Hanazawa
Subjects: sublingual immunotherapy, Japanese cedar pollinosis, biomarker, Medicine
Abstract: Sublingual immunotherapy for Japanese cedar pollinosis can improve the symptoms of allergic rhinitis and modify its natural course. However, sublingual immunotherapy requires a long treatment period and some patients do not respond to treatment. In this study, we aimed to identify biomarkers that could predict the efficacy of sublingual immunotherapy at an early stage. In this study, 40 patients from phase III trials were recruited and divided into good and poor response groups. Using peripheral blood mononuclear cells from before and two months after the start of medication, microarray, discriminant analysis, and real-time polymerase chain reaction were performed to extract candidate genes that could be biomarkers. Furthermore, these genes were validated in 30 patients in general clinical practice. Complement factor H was upregulated in the good response group and downregulated in the poor response group. Complement factor H may be a useful biomarker for predicting the efficacy of sublingual immunotherapy for Japanese cedar pollinosis at early time points after treatment initiation.
Published: 2022
Full Text: View/download PDF

11. Noteworthy Factors to Decide Therapeutic Strategy for Carcinoma ex Pleomorphic Adenoma of Parotid Gland: A Preliminary Study Statistical Analysis of 22 Cases from Single Institution

Author: Kosei Mori, Kazuki Yamasaki, Yuki Morimoto, Takashi Kinoshita, Shunichi Asai, Tomoyuki Arai, Tomohisa Iinuma, Syuji Yonekura, and Toyoyuki Hanazawa
Subjects: carcinoma ex pleomorphic adenoma, CXPA, malignant salivary gland tumor, facial nerve, head and neck cancer, Science
Abstract: Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor, and its prognosis is determined by the histological progression beyond the adenoma capsule. However, a preoperative evaluation of the histological progression remains challenging, and there is no consensus regarding treatment strategies for CXPA. Herein, we aimed to predict the histological progression preoperatively and develop an appropriate treatment strategy for CXPA. We retrospectively reviewed 22 patients with parotid gland CXPA recorded at our hospital. The clinicopathological characteristics were assessed, and survival analysis was performed. T3≤ or N+ were common in widely invasive CXPA (WICXPA) (p < 0.05). A tumor diameter > 40 mm and the N+ status were associated with poor prognosis considering overall survival (OS) and locoregional recurrence rate (LRC) (p < 0.05). Patients with facial nerve paralysis exhibited better OS and LRC than those without facial nerve paralysis. More than 90% of patients with WICXPA experienced distant metastases. Meanwhile, there were no cases of recurrence or death due to intracapsular and minimally invasive CXPA. A preoperative advanced T stage or N+ status was suspected as WICXPA. Tumors > 40 mm in size and N+ status necessitate high-intensity local treatment. Facial nerve invasion can be controlled by nerve resection. Postoperative systemic therapy could control distant metastases.
Published: 2022
Full Text: View/download PDF

12. Investigating Japanese cedar pollen-induced allergic rhinitis and related terms using Google Trends

Author: Tomohisa Iinuma, Syuji Yonekura, Daiju Sakurai, Yosuke Inaba, Yohei Kawasaki, and Yoshitaka Okamoto
Subjects: Immunologic diseases. Allergy, RC581-607
Published: 2020
Full Text: View/download PDF

13. Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Author: Satoshi Suzuki, Daiju Sakurai, Toshioki Sakurai, Syuji Yonekura, Tomohisa Iinuma, Yusuke Okuma, Fumie Ihara, Tomoyuki Arai, Toyoyuki Hanazawa, Emi Fukuda-Kawaguchi, Yasuyuki Ishii, and Yoshitaka Okamoto
Subjects: Immunologic diseases. Allergy, RC581-607
Abstract: Background: Sublingual immunotherapy (SLIT) is an established efficacious approach for the treatment of allergic rhinitis (AR). However, SLIT requires a long administration period to establish stable and adequate responses. This study investigated the efficacy of the sublingual administration of an allergen with liposomes enclosing α-GalCer (α-GC-liposome) as a potential adjuvant in mice with AR. Methods: Mice with AR induced by OVA received the sublingual administration of OVA, α-GC-liposomes, or OVA plus α-GC-liposomes for 7 days. After nasal re-challenge with OVA, nasal symptoms were evaluated. The serum levels of OVA-specific Ig, the cytokine production of CD4+ T cells in the cultures of cervical lymph node (CLN) cells, and the gene expression of CLNs were analyzed. Results: Although IL-4, IL-5 and IL-13 production from CD4+ T cells in CLN cells was significantly inhibited by the sublingual administration of OVA alone in mice with AR induced by OVA, their nasal symptoms were not significantly diminished. However, the combined sublingual administration of α-GC-liposomes and OVA completely suppressed nasal symptoms, downregulated Th2 and Th17 type cytokine production in CD4+ T cells as well as Th2 and Th17 gene expressions, and upregulated Th1 type cytokine production as well as Th1 gene expressions in CLN cells. Additionally, the serum levels of specific IgG2a were promoted, and specific IgE and IgG1 were inhibited. Conclusions: Our findings suggest that the sublingual administration of an allergen with α-GC-liposomes as an adjuvant might increase the therapeutic efficacy and effectiveness of this treatment method. Keywords: Allergic, Liposome, Mice, Natural killer T-Cells, Rhinitis
Published: 2019
Full Text: View/download PDF

14. Complementary and alternative medicine for allergic rhinitis in Japan

Author: Syuji Yonekura, Yoshitaka Okamoto, Daiju Sakurai, Toshioki Sakurai, Tomohisa Iinuma, Heizaburou Yamamoto, Toyoyuki Hanazawa, Shigetoshi Horiguchi, Yuichi Kurono, Kohei Honda, Yuichi Majima, Keisuke Masuyama, Noriaki Takeda, Shigeharu Fujieda, Mitsuhiro Okano, Satoshi Ogino, and Kimihiro Okubo
Subjects: Allergic rhinitis, Complementary and alternative medicine, Conventional treatments, Questionnaire, Unconventional treatments, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Complementary and alternative medicine (CAM) is extensively used in patients with allergic diseases worldwide. The purpose of this study was to investigate the actual situation of CAM practice in the treatment of allergic rhinitis. Methods: We distributed questionnaires to otolaryngologists at 114 facilities in Japan. The subjects who participated in this study included children
Published: 2017
Full Text: View/download PDF

15. Characteristics of the Chiba Environmental Challenge Chamber

Author: Sawako Hamasaki, Yoshitaka Okamoto, Syuji Yonekura, Yusuke Okuma, Toshioki Sakurai, Tomohisa Iinuma, Heizaburo Yamamoto, Daiju Sakurai, Shigetoshi Horiguchi, and Masahiko Yokota
Subjects: environmental challenge chamber (ECC), Japanese cedar pollinosis, seasonal allergic rhinitis (SAR), validation study, α chamber, Immunologic diseases. Allergy, RC581-607
Abstract: Background: An environmental challenge chamber (ECC), which we refer to as the α-chamber, was built at Chiba University in 2008. The aim of this study was to validate the functionality of the ECC. Methods: The stability of the pollen distribution and concentration in the ECC and symptoms of patients with Japanese cedar pollinosis induced by cedar pollen exposure were examined. Carryover effects of symptoms induced by different exposure protocols and correlations between symptoms induced in the ECC and those in the natural cedar pollen season were also determined. All the studies using the α-chamber were conducted out of the cedar pollen season. Results: The severity of symptoms in the chamber reached a peak about 2 hours after the start of pollen exposure and plateaued thereafter. After subjects left the chamber, the symptoms persisted for several days. There was no significant difference between the severity of symptoms at exposure levels of 8000 and 12000 grains/m3. The symptoms were significantly increased by exposure for 3 consecutive days; however, there were no carryover effects in a study performed with a two-week interval. The total nasal symptom score (TNSS) in the natural pollen season showed a weak correlation with the mean TNSS on the day of exposure and the following 3 days. Symptoms in the ECC also had weak correlations with those in the early natural pollen season. Conclusions: The ECC under well-controlled conditions is suitable for clinical studies and might accelerate development of treatment for seasonal allergic rhinitis. A complete evaluation requires inclusion of the persistent reaction after subjects leave the ECC.
Published: 2014
Full Text: View/download PDF

16. The USP7-STAT3-granzyme-Par-1 axis regulates allergic inflammation by promoting differentiation of IL-5-producing Th2 cells.

Author: Jin Kumagai, Masahiro Kiuchi, Kota Kokubo, Hiroyuki Yagyu, Masahiro Nemoto, Kaori Tsuji, Ken Nagahata, Atsushi Sasaki, Takahisa Hishiya, Miki Onoue, Rie Shinmi, Yuri Sonobe, Tomohisa Iinuma, Syuji Yonekura, Jun Shinga, Toyoyuki Hanazawa, Haruhiko Koseki, Toshinori Nakayama, Koutaro Yokote, and Kiyoshi Hirahara
Subjects: TH2 cells, DEUBIQUITINATING enzymes, MITOGEN-activated protein kinases, PROTEASE-activated receptors, SERINE proteinases, ASTHMATICS
Abstract: Uncontrolled type 2 immunity by type 2 helper T (Th2) cells causes intractable allergic diseases; however, whether the interaction of CD4+ T cells shapes the pathophysiology of allergic diseases remains unclear. We identified a subset of Th2 cells that produced the serine proteases granzyme A and B early in differentiation. Granzymes cleave protease-activated receptor (Par)-1 and induce phosphorylation of p38 mitogen-activated protein kinase (MAPK), resulting in the enhanced production of IL-5 and IL-13 in both mouse and human Th2 cells. Ubiquitin-specific protease 7 (USP7) regulates IL-4-induced phosphorylation of STAT3, resulting in granzyme production during Th2 cell differentiation. Genetic deletion of Usp7 or Gzma and pharmacological blockade of granzyme B ameliorated allergic airway inflammation. Furthermore, PAR-1+ and granzyme+ Th2 cells were colocalized in nasal polyps from patients with eosinophilic chronic rhinosinusitis. Thus, the USP7-STAT3-granzymes-Par-1 pathway is a potential therapeutic target for intractable allergic diseases. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

17. Two cases of adenoid cystic carcinoma of the external auditory canal

Author: Yuki Takeyama, Ichiro Fukumoto, Shuji Yonekura, Kazuki Yamasaki, Tomohisa Iinuma, Takashi Kinoshita, Yukiyoshi Mita, Yoshihiro Matsuba, Kengo Shiraishi, Kosei Mori, Toshimitsu Nemoto, and Toyoyuki Hanazawa
Published: 2022

18. Resection of Nasal Mucosal Melanoma with Endoscopic Fenestration of the Nasal Septum: A Case Report

Author: Kazuki Yamasaki, Toyoyuki Hanazawa, Junya Kurita, Yukiyoshi Mita, Tomoyuki Arai, Tomohisa Iinuma, Yuichiro Ohtsuka, and Syuji Yonekura
Subjects: General Medicine
Published: 2022

19. Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases

Author: Atsushi Onodera, Kota Kokubo, Mikiko Okano, Miki Onoue, Masahiro Kiuchi, Chiaki Iwamura, Tomohisa Iinuma, Motoko Y. Kimura, Nobuyuki Ebihara, Toyoyuki Hanazawa, Toshinori Nakayama, and Kiyoshi Hirahara
Subjects: Pharmacology, Pharmacology (medical)
Published: 2023

20. Characteristics of Japanese cypress pollen-induced allergic rhinitis by environmental challenge chamber

Author: Takeshi Suzuki, Toyoyuki Hanazawa, Yoshitaka Okamoto, Tomohisa Iinuma, Daiju Sakurai, Heizaburou Yamamoto, Sawako Hamasaki, Minami Koriyama, Yusuke Okuma, and Syuji Yonekura
Subjects: Horticulture, Japanese cypress pollen, Immunology and Allergy, General Medicine, Biology, Immunologic diseases. Allergy, RC581-607
Published: 2022

21. Characterization of eosinophils and natural killer cells in nasal polyps and peripheral blood in eosinophilic chronic rhinosinusitis patients

Author: Kaori Tsuji, Ami Aoki, Atsushi Onodera, Masahiro Kiuchi, Kota Kokubo, Yuki Morimoto, Tomohisa Iinuma, Toyoyuki Hanazawa, Toshinori Nakayama, and Kiyoshi Hirahara
Subjects: Immunology and Allergy, General Medicine
Published: 2022

22. Precision medicine reaching out to the patients in allergology – a German-Japanese workshop report

Author: Eckard Hamelmann, Martin Wagenmann, Hiroyuki Nagase, Tomohisa Iinuma, Sakura Sato, Thilo Jakob, Susanne Krauss-Etschmann, Kenji Izuhara, Thomas Werfel, Eistine Boateng, Katharina Blumchen, Oliver Pfaar, Taiji Nakano, Christian Taube, Margitta Worm, Saeko Nakajima, and Harald Renz
Subjects: medicine.medical_specialty, Allergen immunotherapy, Allergy, microbiome, Unmet needs, German, Food allergy, medicine, biologics, General Environmental Science, allergic rhinitis, atopic dermatitis, business.industry, General Engineering, Opinion leadership, Atopic dermatitis, asthma, medicine.disease, Precision medicine, language.human_language, Family medicine, insect venom allergy, language, allergen immunotherapy, General Earth and Planetary Sciences, Workshop Report, business
Abstract: An expert workshop in collaboration of the German Society of Allergy and Clinical Immunology (DGAKI) and the Japanese Society of Allergy (JSA) provided a platform for key opinion leaders of both countries aimed to join expertise and to highlight current developments and achievements in allergy research. Key domains of the meeting included the following seven main sections and related subchapters: 1) basic immunology, 2) bronchial asthma, 3) prevention of allergic diseases, 4) food allergy and anaphylaxis, 5) atopic dermatitis, 6) venom allergy, and 7) upper airway diseases. This report provides a summary of panel discussions of all seven domains and highlights unmet needs and project possibilities of enhanced collaborations of scientific projects. © Dustri-Verlag Dr. K. Feistle.
Published: 2021

23. A case report of oropharyngeal clear cell carcinoma with revised pathological diagnosis after multi-gene cancer panel testing

Author: Keiichi Koshizuka, Toyoyuki Hanazawa, Takashi Kinoshita, Tomohisa Iinuma, Syuji Yonekura, and Kazuki Yamasaki
Subjects: Oncology, medicine.medical_specialty, Otorhinolaryngology, business.industry, Internal medicine, Clear cell carcinoma, Medicine, Cancer, business, medicine.disease, Pathological, Multi gene
Published: 2021

24. Three cases of benign symmetric lipomatosis of the neck

Author: Takeshi Suzuki, Tomohisa Iinuma, Toyoyuki Hanazawa, Shuji Yonekura, Miki Sunagane, Keiichi Koshizuka, Yuji Ohki, Takashi Kinoshita, and Kazuki Yamasaki
Subjects: medicine.medical_specialty, business.industry, Family medicine, Medicine, business
Published: 2020

25. A clinical study of sinonasal teratocarcinosarcoma: Report of four cases

Author: Toyoyuki Hanazawa, Rie Shimmi, Tomohisa Iinuma, Yuji Ohki, Daiju Sakurai, and Kazuki Yamasaki
Subjects: Clinical study, medicine.medical_specialty, Oncology, Otorhinolaryngology, Sinonasal teratocarcinosarcoma, medicine, Dermatology
Published: 2020

26. Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic T

Author: Tomohisa, Iinuma, Masahiro, Kiuchi, Kiyoshi, Hirahara, Junya, Kurita, Kota, Kokubo, Hiroyuki, Yagyu, Riyo, Yoneda, Tomoyuki, Arai, Yuri, Sonobe, Masaki, Fukuyo, Atsushi, Kaneda, Syuji, Yonekura, Toshinori, Nakayama, Yoshitaka, Okamoto, and Toyoyuki, Hanazawa
Subjects: Sublingual Immunotherapy, Transforming Growth Factor beta, Cryptomeria, Leukocytes, Mononuclear, Humans, Immunologic Factors, Interleukin-2, Rhinitis, Allergic, Seasonal, Allergens, Rhinitis, Allergic, Biomarkers
Abstract: Allergic rhinitis is a growing problem worldwide. Currently the only treatment that can modify the disease is antigen-specific immunotherapy, but its mechanism of action is not fully understood.We comprehensively investigated the role and changes of antigen-specific T cells before and after sublingual immunotherapy (SLIT) for Japanese cedar pollinosis.We cultured peripheral blood mononuclear cells obtained both before and 1 year after initiating SLIT and used a combination of single-cell RNA sequencing and repertoire sequencing. To investigate biomarkers, we used cells from patients participating a phase 2/3 trial of SLIT tablets for Japanese cedar pollinosis and cells from outpatients with good and poor response.Antigen-stimulated culturing after SLIT led to clonal expansion of TThe combination of single-cell RNA sequencing and repertoire analysis helped reveal part of the underlying mechanism: SLIT promotes the expression of MSC on pathogenic T
Published: 2021

27. A case of jugular bulb diverticulum causing pulsatile tinnitus

Author: Toyoyuki Hanazawa, Kazuki Yamasaki, Yukiyoshi Mita, Tomohisa Iinuma, Ichiro Fukumoto, Yuri Sonobe, and Shuji Yonekura
Subjects: Medicine (General), medicine.diagnostic_test, business.industry, Case Report, Physical examination, Case Reports, General Medicine, Anatomy, medicine.disease, medicine.anatomical_structure, surgical procedures, operative, R5-920, Jugular bulb, Pulsatile Tinnitus, Temporal bone, otorhinolaryngologic diseases, jugular bulb diverticulum, Medicine, Cortical bone, pulsatile tinnitus, business, Diverticulum, high jugular bulb
Abstract: If you suspect pulsatile tinnitus from a medical interview, you should check for jugular bulb diverticulum and cortical bone defects on temporal bone CT, in addition to thorough physical examination and contrast‐enhanced imaging.
Published: 2021

28. Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic TH2 cells and clonal conversion

Author: Tomohisa Iinuma, Masahiro Kiuchi, Kiyoshi Hirahara, Junya Kurita, Kota Kokubo, Hiroyuki Yagyu, Riyo Yoneda, Tomoyuki Arai, Yuri Sonobe, Masaki Fukuyo, Atsushi Kaneda, Syuji Yonekura, Toshinori Nakayama, Yoshitaka Okamoto, and Toyoyuki Hanazawa
Subjects: Immunology, Immunology and Allergy
Published: 2022

29. Efficacy of Desloratadine and Levocetirizine in Patients with Cedar Pollen-Induced Allergic Rhinitis: A Randomized, Double-Blind Study

Author: Syuji Yonekura, Yohei Kawasaki, Daiju Sakurai, Riyo Yoneda, Toyoyuki Hanazawa, Toshioki Sakurai, Tomohisa Iinuma, Junya Kurita, and Yoshitaka Okamoto
Subjects: Adult, Male, Histamine H1 Antagonists, Non-Sedating, medicine.medical_specialty, medicine.medical_treatment, Immunology, Placebo, Gastroenterology, Levocetirizine, Placebos, Double blind study, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Clinical endpoint, Humans, Immunology and Allergy, 030223 otorhinolaryngology, Cedrus, chemistry.chemical_classification, Desloratadine, Cross-Over Studies, business.industry, Rhinitis, Allergic, Seasonal, General Medicine, Loratadine, Cetirizine, Clinical trial, 030228 respiratory system, chemistry, Pollen, Female, Antihistamine, business, medicine.drug, Tricyclic
Abstract: Background: No comparative study of antihistamines that differ in structural system has been conducted in allergic rhinitis. Objective: This was a randomized, double-blind, crossover comparative study to verify the efficacy of antihistamines that differ in structural system. Methods: A total of 50 patients with moderate or more severe Japanese cedar pollen-induced allergic rhinitis were randomized to receive either placebo, desloratadine 5 mg (a tricyclic), or levocetirizine 5 mg (a piperazine). One dose of the study drug was orally administered at 9 pm on the day before a pollen exposure test, which was performed for 3 h (9 a.m. to 12 p.m.) to assess symptoms in an environmental challenge chamber (ECC). Nasal and ocular symptoms were compared at an airborne pollen level of 8,000 grains/m3. The primary endpoint was mean total nasal symptom score (TNSS) from 120 to 180 min in the ECC. Subjects with a difference of ≥1 in TNSS between 2 drugs were extracted to the relevant drug-responsive group. Results: The difference in TNSS from placebo was –2.42 (p < 0.0001) with levocetirizine and –1.66 (p < 0.01) with desloratadine, showing that both drugs were significantly more effective than placebo in controlling symptoms, but with no statistically significant difference between the 2 drugs. There were 12 subjects in the desloratadine-responsive group and 24 subjects in the levocetirizine-responsive group, with no contributor to response was detected. Conclusion: Levocetirizine tended to control nasal symptoms more effectively than desloratadine. However, the response to each antihistamine varied among individuals and the predictors to the response are unknown. Clinical Trial Registration number: UMIN ID: UMIN000029653.
Published: 2019

30. Measuring the Anti-moesin Antibody Titer May Diagnose Patients with Early Stage Granulomatosis with Polyangiitis Limited to the Upper Respiratory Tract

Author: Daiju Sakurai, Tomohisa Iinuma, Yuichiro Otsuka, Toyoyuki Hanazawa, Yoshitaka Okamoto, Naoki Kunii, Kazuki Yamasaki, and Kazuo Suzuki
Subjects: Pathology, medicine.medical_specialty, medicine.anatomical_structure, business.industry, Moesin, medicine, Antibody titer, Stage (cooking), business, Granulomatosis with polyangiitis, medicine.disease, Respiratory tract
Published: 2019

31. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases -Meeting Report (Part 1)

Author: Elaine Colgan, Mario Sánchez-Borges, Jim Phillips, Ignacio J. Ansotegui, Bolesław Samoliński, Olga Lourenço, Giorgio Walter Canonica, F. Portejoie, Isabella Annesi-Maesano, Gabrielle L. Onorato, Victoria Cardona, João O. Malva, Eugene Cash, Christine Rolland, Hilary Pinnock, Samantha Walker, Yoshitaka Okamoto, Ana Maria Carriazo, Lorenzo Cecchi, Nikos G. Papadopoulos, Jean Bousquet, L. T. T. Le, João Fonseca, Oliver Pfaar, Luis Caraballo, Elísio Costa, Maritta Perala, Pablo Quinones-Delgado, Torsten Zuberbier, Holger J. Schünemann, Tomohisa Iinuma, Enrica Menditto, Maddalena Illario, Nils E. Billo, Arunas Valiulis, Sinthia Bosnic-Anticevich, Josep M. Antó, Nick A. Guldemond, Maria Teresa Ventura, Claus Bachert, Wytske Fokkens, Lars Münter, Mohamed H. Shamji, Ioana Agache, Ulysse Rodts, Daniel Laune, Sanna Toppila-Salmi, Joaquim Mullol, Ioanna Tsiligianni, Motohiro Ebisawa, Isabelle Bosse, Samuel Benveniste, Arzu Yorgancioglu, Alkis Togias, M. Bewick, Nhân Pham-Thi, Stephen R. Durham, Moises A. Calderon, Marina Erhola, Violeta Kvedariene, Omar S. Usmani, Alvaro A. Cruz, Anna Bedbrook, Abigail Phillips, Desiree Larenas-Linneman, Guy Brusselle, Gert Marien, Dana Wallace, David Somekh, Sian Williams, Wienczyslawa Czarlewski, Ludger Klimek, Piotr Kuna, Jean-Luc Fauquert, Rianne van der Kleij, Derek K. Chu, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris], Transilvania University of Brasov, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), Ghent University Hospital, Centre de Recherche en Informatique (CRI), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], iQ4U consultants Ltd, University of Joensuu, The University of Sydney, Imperial College London, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Institute for Immunological Research (University of Cartagena), Vall d'Hebron University Hospital [Barcelona], Servicio Andaluz de Salud, Nova Southeastern University (NSU), Azienda Sanitaria di Prato, McMaster University [Hamilton, Ontario], DEPARTMENT OF HEALTH ( Social Services and Public Safety), Universidade do Porto, Universidade Federal da Bahia (UFBA), UCB Pharma, Colombes, Sagamihara National Hospital, National Institute for Health and Welfare [Helsinki], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Faculdade de Medicina da Universidade do Porto (FMUP), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Chiba University Hospital, 'Federico II' University of Naples Medical School, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Medical University of Łódź (MUL), Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], KYomed INNOV, Ho Chi Minh City University of Technology (HCMUT), Faculty of Health Sciences and CICS-UB (Health Sciences Research Centre), University of Coimbra [Portugal] (UC), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Department of Public Health [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), University of Manchester [Manchester], University of Athens Medical School [Athens], University of Oulu, Philipps University of Marburg, Cardiff University, University of Edinburgh, Regional Government for Equality, Medical University of Warsaw - Poland, Centro Medico-Docente La Trinidad, Department of Clinical Epidemiology and Biostatistics and Medicine, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), University of Helsinki, University of Crete [Heraklion] (UOC), National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, King's College Hospital (KCH), Leiden University Medical Center (LUMC), University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Humboldt-Universität zu Berlin, Association Asthme et Allergie, Health Services Management & Organisation (HSMO), University Hospital Montpellier, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, EUFOREA, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, Allergy Department, Pasteur Institute, Paris, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Sorbonne Universités, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiolog a y Salud Pública (CIBERESP), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd., London, United Kingdom, Joensuu, Finland, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Imperial College London, National Heart and Lung Institute, London, United Kingdom, Personalized Medicine Clinic Asthma and Allergy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron and ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, College of Psychology, Nova Southeastern University, School-related Psychological Assessments and Clinical Interventions Clinic, Ft Lauderdale, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, UCIBIO, REQUIMTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Executive Committee, Bahia, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan, National Institute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d’Allergologie de l’Enfant, Pôle Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina, Universidade do Porto, Medida, Lda, Porto, Portugal, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Faculty of Health Sciences, CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Cl nic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P and A Kyriakou', University of Athens, Athens, Greece, University of Oulu, Faculty of Medicine, Oulun Yliopisto, Finland, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany, Department of Health and Social Services, Welsh Government, Cardiff, United Kingdom, Centre For Empowering Patients and Communities, Dublin, Ireland, Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain, Association Asthme et Allergie, Paris, France, KanopyMed, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, Immunomodulation and Tolerance Group, Imperial College London, London, United Kingdom, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, European Health Futures Forum (EHFF), Dromahair, Ireland, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital, Airways Disease Section, London, United Kingdom, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, Institut Pasteur [Paris] (IP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hospital Quirónsalud Bizkaia [Bilbao], Mines Paris - PSL (École nationale supérieure des mines de Paris), Universidade do Porto = University of Porto, Sagamihara National Hospital [Kanagawa, Japan], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Philipps Universität Marburg = Philipps University of Marburg, Centro Médico Docente La Trinidad, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Humboldt University Of Berlin, Salvy-Córdoba, Nathalie, Universiteit Leiden, Bousquet, J., Pham-Thi, N., Bedbrook, A., Agache, I., Annesi-Maesano, I., Ansotegui, I., Anto, J. M., Bachert, C., Benveniste, S., Bewick, M., Billo, N., Bosnic-Anticevich, S., Bosse, I., Brusselle, G., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Carriazo, A. M., Cash, E., Cecchi, L., Chu, D. K., Colgan, E., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S., Ebisawa, M., Erhola, M., Fauquert, J. -L., Fokkens, W. J., Fonseca, J. A., Guldemond, N., Iinuma, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linneman, D., Laune, D., Le, L. T. T., Lourenco, O., Malva, J. O., Marien, G., Menditto, E., Mullol, J., Munter, L., Okamoto, Y., Onorato, G. L., Papadopoulos, N. G., Perala, M., Pfaar, O., Phillips, A., Phillips, J., Pinnock, H., Portejoie, F., Quinones-Delgado, P., Rolland, C., Rodts, U., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Shamji, M., Somekh, D., Togias, A., Toppila-Salmi, S., Tsiligianni, I., Usmani, O., Walker, S., Wallace, D., Valiulis, A., Van Der Kleij, R., Ventura, M. T., Williams, S., Yorgancioglu, A., and Zuberbier, T.
Subjects: Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, Allergic and chronic respiratory diseases, [SDV.IMM] Life Sciences [q-bio]/Immunology, Allergic rhinitis - Asthma - Multimorbidity, Health care system, Health literacy, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Health care, medicine, Patient participation, mHealth, Asthma, Rhinitis, [SDV.EE]Life Sciences [q-bio]/Ecology, environment, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Newsletter of GARD Section, business.industry, Environmental exposure, medicine.disease, 3. Good health, Integrated care, [SDV.EE] Life Sciences [q-bio]/Ecology, environment, 030228 respiratory system, 13. Climate action, Family medicine, [SDV.IMM]Life Sciences [q-bio]/Immunology, 030211 gastroenterology & hepatology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system for integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (2), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life integrated care pathways (ICPs) (3)-centred around the patient with rhinitis and using mHealth monitoring of environmental exposure (4).An expert meeting took place at the Pasteur Institute in Paris, December 3, 2018. The aim was to discuss next-generation care pathways: (I) Patient participation, health literacy and self-care through technology-assisted “patient activation”; (II) Implementation of care pathways by pharmacists and (III) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) assessed by mobile technology.The EU (5) and global political agendas are of great importance in supporting health care transformation. MASK has been recognized by DG Santé as a Good Practice (6) in the field of digitally-enabled, integrated, person-centred care.The one-day meeting objectives were clear (Figure 1). The meeting was followed by a workshop. The present paper reports the background of the two-day meeting.
Published: 2019

32. A case of jugular bulb diverticulum causing objective tinnitus

Author: Ichiro Fukumoto, Kazuki Yamasaki, Shuji Yonekura, Tomohisa Iinuma, Yukiyoshi Mita, Yuri Sonobe, and Toyoyuki Hanazawa
Subjects: surgical procedures, operative, nervous system, cardiovascular system, otorhinolaryngologic diseases, therapeutics
Abstract: Anatomical anomalies of the jugular bulb include a high jugular bulb and deficiency of the cortical bone. Most cases are asymptomatic; however, they may present with tinnitus, hearing loss, dizziness. We encountered a rare case of jugular bulb diverticulum with deficiency of the cortical bone that caused objective tinnitus.
Published: 2021

33. Evaluation of shoseiryuto for seasonal allergic rhinitis, using an environmental challenge chamber

Author: Junya Kurita, Syuji Yonekura, Tomohisa Iinuma, Riyo Yoneda, Sakiko Imamoto, Toyoyuki Hanazawa, Yohei Kawasaki, Takao Namiki, and Yoshitaka Okamoto
Subjects: Pulmonary and Respiratory Medicine, Immunology, Immunology and Allergy
Abstract: Complementary and alternative medicine, including Japanese traditional medicine (JTM), has been used for various allergic diseases, but the evidence is limited. Shoseiryuto (Xiao-Qing-Long-Tang), one of the representative JTM drugs, is frequently used to treat allergic rhinitis (AR). However, its efficacy for seasonal AR has not been fully established. Using an Environmental challenge chamber (ECC), we evaluated the therapeutic effects of shoseiryuto on AR induced by Japanese cedar pollen (JCP).A placebo-controlled double-blind crossover study with shoseiryuto was conducted using the ECC. The shoseiryuto or placebo was orally administered from 2 weeks before the exposure test. The pollen exposure test was conducted for 3 h, and the pollen concentration was set at 8000 pollen/mThe results of the 46 participants were analyzed, and no significant side effects were detected. There was no significant difference in TNSS during pollen exposure for 3 h in the ECC between the shoseiryuto and placebo groups. However, some symptoms were improved in the shoseiryuto group after leaving the ECC. There was no significant correlation between the "fluid retention pattern" and TNSS. In immunological studies, shoseiryuto did not inhibit Th2-type cytokine production and mRNA expression.Oral administration of shoseiryuto from 2 weeks before pollen exposure did not prevent or inhibit immediate symptoms of AR induced by JCP in the ECC. Further study is needed to reevaluate the shoseiryuto specific "pattern" in JTM.
Published: 2021

34. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA

Author: Jere Reijula, De Yun Wang, Ralph Mösges, Tomohisa Iinuma, Jean Luc Fauquert, Nelson Rosario, Yehia El-Gamal, René Maximiliano Gómez, Tari Haahtela, Vincenzo Patella, Lorenzo Cecchi, Petr Panzner, Yoshitaka Okamoto, Oliver Pfaar, Luis Caraballo, Paulo Augusto Moreira Camargos, Filip Raciborski, Florin Mihaltan, Ken Ohta, Brian J. Lipworth, Kimi Okubo, Juan Carlos Ivancevich, Fulvio Braido, Ioana Agache, Frederico S. Regateiro, Neven Miculinic, Tuula Vasankari, R. Emuzyte, Arunas Valiulis, Yousser Mohammad, Torsten Zuberbier, Osman M. Yusuf, Ewa Jassem, Cezmi A. Akdis, Jean Bousquet, Alessandro Fiocchi, Jan Hagemann, Claus Bachert, Davor Plavec, K. S. Bennoor, Marek Jutel, Désirée Larenas-Linnemann, Stephen Montefort, Stefano Del Giacco, Przemyslaw Kardas, Erkka Valovirta, Mark S. Dykewicz, Antonio Valero, Wienczyslawa Czarlewski, Thomas B. Casale, Gabrielle L. Onorato, Omer Kalayci, Ludger Klimek, Joaquin Sastre, João Fonseca, Siân Williams, Karl Christian Bergmann, Marek Niedoszytko, Bilun Gemicioglu, Mario E. Zernotti, Musa Khaitov, H. Neffen, Robert M. Naclerio, Joaquim Mullol, Ana Pereira, Piotr Kuna, Michael Makris, Maria Teresa Ventura, Ioanna Tsiligianni, Dirceu Solé, Arzu Yorgancioglu, Charlotte Suppli-Ulrik, M. Gotua, Emmanuel P. Prokopakis, Dana Wallace, Jorge Maspero, Wytske Fokkens, Eckard Hamelmann, Antonino Romano, Dejan Dokic, Todor A. Popov, Violeta Kvedariene, Derek K. Chu, Anna Bedbrook, Dermot Ryan, Motohiro Ebisawa, Tomas Chivato, Giovanni Passalacqua, Menachem Rottem, Mário Morais-Almeida, Victoria Cardona, Bolesław Samoliński, Cristiana Stellato, Nikolaos G. Papadopoulos, Milan Sova, Jaime Correia-de-Sousa, Sietze Reitsma, Cemal Cingi, Francesca Puggioni, Robyn E O'Hehir, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, HUS Internal Medicine and Rehabilitation, Department of Public Health, Clinicum, Keuhkosairauksien yksikkö, Helsinki University Hospital Area, University of Helsinki, University Medical Center of the Johannes Gutenberg-University Mainz, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Wrocław [Poland] (UWr), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Transilvania University of Brasov, Humboldt University Of Berlin, Medical Consulting Czarlewski, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MASK-air, Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], National Institute of Diseases of the Chest and Hospital (NIDCH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ospedale Policlinico San Martino [Genoa], Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), University of Cartagena, Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Vall d'Hebron University Hospital [Barcelona], Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], CEU-San Pablo University and HM-Hospitals School of Medicine, McMaster University [Hamilton, Ontario], Eskisehir Osmangazi University, Universidade do Minho = University of Minho [Braga], Life and Health Sciences Research Institute [Braga] (ICVS), University of Minho [Braga], The International Primary Care Respiratory Group (IPCRG), Università degli Studi di Cagliari = University of Cagliari (UniCa), Sts. Cyril and Methodius University, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Vilnius University [Vilnius], Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Bambino Gesù Children’s Hospital [Rome, Italy], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, CUF Porto Hospital, Cerrahpasa Faculty of Medicine, Istanbul University, ALAS Medical Institute, Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universität Bielefeld = Bielefeld University, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Medical University of Gdańsk, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Medical University of Łódź (MUL), Federal Medicobiological Agency [Moscow, Russian Federation], Hospital Medica Sur [Mexico City, Mexico], Ninewells Hospital and Medical School [Dundee], University General Hospital ' Attikon ' [Athens, Greece], Argentine Association of Allergy and Immunology, Marius Nasta Institute of Pneumology, Tishreen University, Université de Damas = Damascus University, University of Malta [Malta], Hospital CUF Descobertas, Clinical Research International Ltd [Hamburg, Germany] (CRI), Johns Hopkins University School of Medicine [Baltimore], Nemours/Alfred I. du Pont Hospital for Children, Monash University [Melbourne], Tokyo National Hospital, Nippon Medical School [Tokyo, Japon], Medicine Charles University and General Faculty Hospital in Prague, Royal Manchester Children's Hospital, University of Manchester [Manchester], Università degli studi di Genova = University of Genoa (UniGe), 'Santa Maria della Speranza' Hospital, Philipps Universität Marburg = Philipps University of Marburg, J.J. Strossmayer University of Osijek, Children’s Hospital Srebrnjak [Zagreb, Croatia], St. Ivan Rilski University Hospital, University of Crete [Heraklion] (UOC), IRCCS Humanitas [Rozzano, Italy], Medical University of Warsaw - Poland, Centro Hospitalar e Universitário [Coimbra], Amsterdam UMC - Amsterdam University Medical Center, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Clinica G.B. Morgagni (Fondazione Mediterranea), Pontifical Catholic University of Paraná (PUCPR), Pontifícia Universidade Católica do Paraná (PUCPR), Ha’Emek Medical Center [Afula, Israel], Pediatric Endocrine Institute [Afula, Israel], Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Edinburgh, Federal University of Sao Paulo (Unifesp), University Hospital Olomouc [Czech Republic], University of Salerno (UNISA), Copenhagen University Hospital, Universitat de Barcelona (UB), European Academy of Paediatrics (EAP/UEMS-SP), University of Turku, Suomen Terveystalo Allergy Clinic, Finnish Lung Health Association, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Nova Southeastern University (NSU), Yong Loo Lin School of Medicine [Singapore], Department of Biology, Faculty of Sciences & Liberal Arts, Celal Bayar University, Manisa Celal Bayar University, The Allergy & Asthma Institute, Pakistan (IPCRG), Universidad Nacional de Villa María, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Allergiezentrum Wiesbaden, Salvy-Córdoba, Nathalie, Ear, Nose and Throat, and AII - Inflammatory diseases
Subjects: 0301 basic medicine, Allergy, MESH: Asthma, Common Cold, allergic rhinitis, common cold, cough, COVID-19, smell, Consensus, Humans, SARS-CoV-2, Asthma, Rhinitis, Allergic, Disease, Care, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Immunology and Allergy, MESH: COVID-19, Rhinitis, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Common cold, 3. Good health, MESH: Rhinitis, Allergic, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Original Article, medicine.symptom, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Immunology, Signs and symptoms, Asymptomatic, 03 medical and health sciences, Allergic, COVID‐19, Internal medicine, medicine, MESH: SARS-CoV-2, MESH: Consensus, MESH: Humans, business.industry, Rhinitis, Sinusitis, and Upper Airway Disease, CARE, medicine.disease, 030104 developmental biology, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, 3121 General medicine, internal medicine and other clinical medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ORIGINAL ARTICLES, Airway, business, MESH: Common Cold
Abstract: Background Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001). Conclusions This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.
Published: 2021

35. Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

Author: Patrick Lemell, Tomohisa Iinuma, Y. Okamoto, Priti R. Patel, Robert L. Jacobs, L Haya, Jimmy Yang, P.J. de Kam, Stephen R. Durham, Alkis Togias, P. Devillier, S. Kaul, Oliver Pfaar, Henrik H. Jacobi, F. De Blay, Vera Mahler, Anne K. Ellis, Marek Jutel, Christoph Willers, A. Gherasim, K. C. Bergmann, P. Zieglmayer, Ss Bonini, Cynthia G. Rather, Mark Larché, A. Sager, René Zieglmayer, Friedrich Horak, Nathalie Domis, Jens M. Hohlfeld, S Kelly, Anne-Marie Salapatek, Ronald L. Rabin, Torben Sigsgaard, T. Zuberbier, Hendrik Nolte, Ludger Klimek, Enrico Compalati, and Publica
Subjects: Allergen immunotherapy, medicine.medical_specialty, Allergy, Immunology, technical standards, medicine, Immunology and Allergy, Humans, allergen exposure chambers, Intensive care medicine, COVID-19, clinical trials, Allergie, allergen immunotherapy, Field exposure, Task force, business.industry, Technical information, Allergic asthma, Allergens, respiratory system, medicine.disease, Rhinitis, Allergic, Asthma, Clinical trial, Desensitization, Immunologic, Pollen, ALLERGEN EXPOSURE, business
Abstract: Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated. On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments. Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non-contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.
Published: 2021

36. Local fungus-specific Immunoglobulin E production in chronic rhinosinusitis with nasal polyps

Author: D. Sakurai, Yoshitaka Okamoto, Katsuhiko Kamei, Takahito Toyotome, H. Yamamoto, Tomohisa Iinuma, Yuji Ohki, Maki Yahiro, and Shuji Yonekura
Subjects: Fungus, Disease, Immunoglobulin E, Pathogenesis, 03 medical and health sciences, Nasal Polyps, 0302 clinical medicine, Immune system, Antigen, Humans, Medicine, Nasal polyps, Sinusitis, 030223 otorhinolaryngology, Antibodies, Fungal, Rhinitis, Asthma, biology, business.industry, Fungi, General Medicine, biology.organism_classification, medicine.disease, Mycoses, Otorhinolaryngology, Case-Control Studies, Chronic Disease, Immunology, biology.protein, business
Abstract: BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease, and its pathogenesis remains controversial. This study aimed to examine the involvement of fungi in CRSwNP pathogenesis. METHODS We enrolled 29 controls and 111 CRSwNP patients. We analyzed fungi in the nasal secretions, serum fungus-specific immunoglobulin E (IgE) levels, and nasal polyp (NP) IgE levels. Moreover, we evaluated the correlation between patients' IgE levels and computed tomography (CT) scores. RESULTS There was no difference in fungal detection rate between CRSwNP patients with and without asthma. Specific IgEs against various antigens were highly detectable in NPs of CRSwNP patients. In CRSwNP patients, fungus-specific IgE levels in NPs were correlated with CT scores. Serum fungus-specific IgEs became undetectable after operation in more than half of the CRSwNP patients without asthma but not in those with asthma. Other serum airborne antigen-specific IgEs did not become undetectable after operation. CONCLUSIONS Fungus-specific IgEs were highly detectable in NPs of CRSwNP patients, and NPs comprised a major region of specific IgE production. Fungi may therefore play an important role in CRSwNP pathogenesis by inducing Th2 immune responses, including IgE synthesis.
Published: 2020

37. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy

Author: Toshinori Nakayama, Shuichi Suzuki, Fumie Ihara, Yoshitaka Okamoto, T. Ito, Toshioki Sakurai, Shuji Yonekura, K. Katayama, Tomoyuki Arai, Ryoji Yagi, Yuki Morimoto, D. Sakurai, Tomohisa Iinuma, and A. Matsuura
Subjects: Adult, Male, 0301 basic medicine, medicine.medical_treatment, Immunology, Placebo, Peripheral blood mononuclear cell, Immunophenotyping, Flow cytometry, Pathogenesis, Young Adult, 03 medical and health sciences, Th2 Cells, Antibody Specificity, T-Lymphocyte Subsets, medicine, Humans, Immunology and Allergy, Sublingual immunotherapy, Lymphocyte Count, House dust mite, Sublingual Immunotherapy, medicine.diagnostic_test, biology, business.industry, Allergens, Immunoglobulin E, biology.organism_classification, Rhinitis, Allergic, Slit, Treatment Outcome, 030104 developmental biology, Cytokine, Cytokines, Female, business, Immunologic Memory, Biomarkers
Abstract: Background Although Th2 cells are well known to play important roles in allergic diseases including allergic rhinitis (AR), the factors that induce and sustain the pathogenesis of AR remain unclear. The recent development of sublingual immunotherapy (SLIT) is expected to allow changes to the underlying pathogenesis of AR. However, which Th2 cell subsets are important in house dust mite-induced AR (HDM-AR), the influence of SLIT on the pathogenic Th2 cells, and the association of Th2 cell subsets with SLIT efficacy have not been clarified. Methods The cytokine production and frequency of HDM-reactive T-cell subsets in peripheral blood mononuclear cells (PBMCs) were evaluated using flow cytometry in 89 HDM-AR patients (placebo [n = 43] and HDM 300 IR [n = 46]) who participated in a placebo-controlled study of SLIT with HDM tablets. All patients provided samples both before treatment as a baseline and at the end of the 52-week study. The PBMCs were stained with CellTrace™ Violet (CTV) before culture with HDM extract, and HDM-reactive T cells were detected as the proliferated cells with diminished CTV. Results HDM-reactive IL-5+ IL-13+ CD27- CD161+ CD4+ cells and ST2+ CD45RO+ CD4+ cells were observed in the peripheral blood from each patient with HDM-AR; these cells significantly decreased after SLIT in the group treated with active tablets. HDM-reactive ST2+ CD45RO+ CD4+ cells were significantly lower in active-responders. Conclusion Allergen-reactive ST2+ CD45RO+ CD4+ cells or those combined with IL-5+ IL-13+ CD27- CD161+ CD4+ cells may be useful as markers indicating the successful treatment of SLIT. These cells may play a crucial role in the pathogenesis of AR as pathogenic memory Th2 cells.
Published: 2018

38. The Relationship of Pollen Dispersal with Allergy Symptoms and Immunotherapy: Allergen Immunotherapy Improves Symptoms in the Late Period of Japanese Cedar Pollen Dispersal

Author: Toshioki Sakurai, Shinya Kaneko, Daiju Sakurai, Yuki Morimoto, Yoshitaka Okamoto, Tomohisa Iinuma, and Syuji Yonekura
Subjects: Adult, Male, Allergen immunotherapy, medicine.medical_specialty, Allergy, Adolescent, Cryptomeria, medicine.medical_treatment, Immunology, Administration, Sublingual, medicine.disease_cause, Severity of Illness Index, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Japan, Pollen, Internal medicine, otorhinolaryngologic diseases, medicine, Humans, Immunology and Allergy, Child, 030223 otorhinolaryngology, Pollen count, Aged, Plant Proteins, Sublingual Immunotherapy, business.industry, Rhinitis, Allergic, Seasonal, food and beverages, General Medicine, Immunotherapy, Antigens, Plant, Middle Aged, Pollen dispersal, medicine.disease, Treatment Outcome, 030228 respiratory system, Late period, Desensitization, Immunologic, Biological dispersal, Female, business
Abstract: Background: The severity of symptoms of pollen-induced allergic rhinitis is affected by the amount of scattered pollen. However, the relationships between the pollen dispersal pattern, symptom severity, and treatment efficacy are not clear. Methods: Between 2007 and 2012, we performed 4 randomized, placebo-controlled studies of sublingual immunotherapy (SLIT) on patients with Japanese cedar-induced allergic rhinitis who lived in or around Chiba, Japan. The participants were asked to avoid using rescue medicines during the cedar pollen season as much as possible and to record their nasal symptoms in allergy diaries. The amount of pollen dispersed daily was quantified using the Durham method, and the season was divided into early and late periods based on the pollen count. Results: A total of 721 patients were enrolled in the 4 studies during the 6-year study period. In the placebo group (n = 349), a correlation was observed between the amount of pollen dispersed and the severity of symptoms in the early but not late period of pollen dispersal. Treatment with SLIT (n = 372) significantly improved symptom severity in the late but not early period. Conclusion: For patients with Japanese cedar pollen-induced allergic rhinitis, the fluctuation of daily pollen dispersal had a minimal effect on the severity of symptoms during the late period. SLIT was remarkably effective in alleviating symptoms during this period but not in the early period.
Published: 2018

39. Complementary and alternative medicine for allergic rhinitis in Japan

Author: Toyoyuki Hanazawa, Kimihiro Okubo, Heizaburou Yamamoto, Noriaki Takeda, Keisuke Masuyama, Tomohisa Iinuma, Toshioki Sakurai, Kohei Honda, Yuichi Majima, Shigeharu Fujieda, Syuji Yonekura, Yuichi Kurono, Shigetoshi Horiguchi, Daiju Sakurai, Yoshitaka Okamoto, Mitsuhiro Okano, and Satoshi Ogino
Subjects: Adult, Complementary Therapies, Male, lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Adolescent, Conventional treatments, media_common.quotation_subject, Alternative medicine, Unconventional treatments, Allergic rhinitis, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Randomized controlled trial, Japan, law, Surveys and Questionnaires, medicine, Humans, Immunology and Allergy, In patient, 030212 general & internal medicine, Practice Patterns, Physicians', media_common, Aged, Aged, 80 and over, Adult patients, business.industry, Questionnaire, Disease Management, General Medicine, Health Care Costs, Middle Aged, Rhinitis, Allergic, 030228 respiratory system, Feeling, Socioeconomic Factors, Complementary and alternative medicine, Health Care Surveys, Physical therapy, Anxiety, Female, medicine.symptom, business, lcsh:RC581-607
Abstract: Background: Complementary and alternative medicine (CAM) is extensively used in patients with allergic diseases worldwide. The purpose of this study was to investigate the actual situation of CAM practice in the treatment of allergic rhinitis. Methods: We distributed questionnaires to otolaryngologists at 114 facilities in Japan. The subjects who participated in this study included children
Published: 2017

40. Investigating Japanese cedar pollen-induced allergic rhinitis and related terms using Google Trends

Author: Yosuke Inaba, Yoshitaka Okamoto, Yohei Kawasaki, Daiju Sakurai, Tomohisa Iinuma, and Syuji Yonekura
Subjects: lcsh:Immunologic diseases. Allergy, Traditional medicine, business.industry, Cryptomeria, Rhinitis, Allergic, Seasonal, General Medicine, Rhinitis, Allergic, Search Engine, Japan, Japanese cedar pollen, Immunology and Allergy, Medicine, Humans, Pollen, business, lcsh:RC581-607, Social Media
Published: 2019

41. Regulatory T cells induce CD4

Author: Fumie, Ihara, Daiju, Sakurai, Mariko, Takami, Toshiko, Kamata, Naoki, Kunii, Kazuki, Yamasaki, Tomohisa, Iinuma, Toshinori, Nakayama, Shinichiro, Motohashi, and Yoshitaka, Okamoto
Subjects: Aged, 80 and over, Clonal Anergy, Cytotoxicity, Immunologic, Immunosuppression Therapy, Male, Squamous Cell Carcinoma of Head and Neck, Middle Aged, T-Lymphocytes, Regulatory, Head and Neck Neoplasms, Humans, Natural Killer T-Cells, Female, Immunologic Surveillance, Cells, Cultured, Aged
Abstract: Due to the strong tumoricidal activities of activated natural killer T (NKT) cells, invariant NKT cell-based immunotherapy has shown promising clinical efficacy. However, suppressive factors, such as regulatory T cells (Tregs), may be obstacles in the use of NKT cell-based cancer immunotherapy for advanced cancer patients. Here, we investigated the suppressive effects of Tregs on NKT cells and the underlying mechanisms with the aim to improve the antitumor activities of NKT cells.Peripheral blood samples were obtained from healthy donors, patients with benign tumors, and patients with head and neck squamous cell carcinoma (HNSCC). NKT cells, induced with α-galactosylceramide (α-GalCer), and monocyte-derived dendritic cells (DCs) were co-cultured with naïve CD4Treg suppression on NKT cell function required cell-to-cell contact and was mediated via impaired DC maturation. NKT cells cultured under Treg-enriched conditions showed a decrease in CD4Tregs exert suppressive effects on NKT cell tumoricidal function by inducing more CD4
Published: 2019

42. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 2)

Author: Josep M. Antó, Nick A. Guldemond, Ulysse Rodts, Bolesław Samoliński, Olga Lourenço, Mohamed H. Shamji, Tomohisa Iinuma, Rianne van der Kleij, Alkis Togias, W. J. Fokkens, Gert Marien, Derek K. Chu, Mario Sánchez-Borges, Daniel Laune, Desiree Larenas-Linneman, Anna Bedbrook, Guy Brusselle, Joaquim Mullol, Lars Münter, Ludger Klimek, Sanna Toppila-Salmi, Eugene Cash, Christine Rolland, Ioanna Tsiligianni, Isabelle Bosse, Dana Wallace, Motohiro Ebisawa, Abigail Phillips, Torsten Zuberbier, G. Walter Canonica, Elísio Costa, Samuel Benveniste, Yoshitaka Okamoto, Holger J. Schünemann, Moises A. Calderon, Sinthia Bosnic-Anticevich, Mike Bewick, Elaine Colgan, Arunas Valiulis, Sian Williams, Samantha Walker, Ignacio J. Ansotegui, David Somekh, Isabella Annesi-Maesano, Victoria Cardona, Wienczyslawa Czarlewski, Claus Bachert, Ana Maria Carriazo, João Fonseca, Nils Billo, Violeta Kvedariene, Ioana Agache, Maria Teresa Ventura, Jim Phillips, Piotr Kuna, Hilary Pinnock, Lorenzo Cecchi, F. Portejoie, Jean-Luc Fauquert, Alvaro A. Cruz, Jean Bousquet, Nikos Papadopoulos, Omar S. Usmani, Gabrielle L. Onorato, Arzu Yorgancioglu, Pablo Quinones-Delgado, Oliver Pfaar, Luis Caraballo, Stephen R. Durham, L. T. T. Le, João O. Malva, Maritta Perala, Enrica Menditto, Nhân Pham-Thi, Marina Erhola, Maddalena Illario, Ear, Nose and Throat, AII - Inflammatory diseases, University Hospital Montpellier, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universitätzu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, EUFOREA, Brussels, Belgium, Allergy Department, Pasteur Institute, Paris, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Universités, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd, London, United Kingdom, Independent Consultant, Joensuu, Finland, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia, Allergist, La Rochelle, France, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Imperial College London-National Heart and Lung Institute, London, United Kingdom, Personalized Medicine Clinic Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences, Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron and ARADyAL research network, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, College of Psychology, Nova Southeastern University, School-related Psychological Assessments and Clinical Interventions Clinic, Ft Lauderdale, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Department of Health, Social Services and Public Safety, Northern Ireland, Belfast, United Kingdom, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Executive Committee, Bahia, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan, National Institute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d’Allergologie de l’Enfant, Pôle Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Medida, Lda Porto, Portugal, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P and A Kyriakou', University of Athens, Athens, Greece, University of Oulu, Faculty of Medicine, Oulun Yliopisto, Finland, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany, Department of Health and Social Services, Welsh Government, Cardiff, United Kingdom, Centre For Empowering Patients and Communities, Dublin, Ireland, Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The, University of Edinburgh, Edinburgh, United Kingdom, Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain, Association Asthme et Allergie, Paris, France, KanopyMed, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, Immunomodulation and Tolerance Group, Imperial College London, and, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, European Health Futures Forum (EHFF), Dromahair, Ireland, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital, Airways Disease Section, London, United Kingdom, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, CHU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, 34295, France, [Bousquet, Jean] Univ Hosp Montpellier, Montpellier, France, [Bousquet, Jean] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Bedbrook, Anna] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Onorato, Gabrielle L.] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Portejoie, Fabienne] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Bousquet, Jean] INSERM, Ageing & Chron Dis Epidemiol & Publ Hlth Approach, VIMA, U1168, Villejuif, France, [Bousquet, Jean] Univ Versailles St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France, [Bousquet, Jean] Euforea, Brussels, Belgium, [Fokkens, Wytske J.] Euforea, Brussels, Belgium, [Marien, Gert] Euforea, Brussels, Belgium, [Bousquet, Jean] Humboldt Univ, Univ Med Berlin, Charite, Berlin, Germany, [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany, [Zuberbier, Torsten] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany, [Nhan Pham-Thi] Pasteur Inst, Allergy Dept, Paris, France, [Agache, Ioana] Transylvania Univ, Fac Med, Brasov, Romania, [Annesi-Maesano, Isabella] INSERM, Depet Inst Pierre Louis Epidemiol & Publ, Epidemiol Allerg & Resp Dis, Paris, France, [Annesi-Maesano, Isabella] Sorbonne Univ, Med Sch St Antoine, Paris, France, [Ansotegui, Ignacio] Hosp Quironsalud Bizkaia, Dept Allergy & Immunol, Erandio, Spain, [Anto, Josep M.] Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain, [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain, [Anto, Josep M.] CIBERESP, Barcelona, Spain, [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium, [Benveniste, Samuel] Broca Hosp, Natl Ctr Expertise Cognit Stimulat CEN STIMCO, Paris, France, [Benveniste, Samuel] PSL Res Univ, Mines ParisTech CRI, Fontainebleau, France, [Bewick, Mike] iQ4U Consultants Ltd, London, England, [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia, [Bosnic-Anticevich, Sinthia] Woolcock Emphysema Ctr, Glebe, NSW, Australia, [Bosnic-Anticevich, Sinthia] Sydney Local Hlth Dist, Glebe, NSW, Australia, [Brusselle, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium, [Calderon, Moses A.] Imperial Coll London, Natl Heart & Lung Inst, London, England, [Usmani, Omar] Imperial Coll London, Natl Heart & Lung Inst, London, England, [Canonica, G. Walter] IRCCS, Humanitas Clin & Res Ctr, Personalized Med Clin Asthma & Allergy, Rozzano, MI, Italy, [Canonica, G. Walter] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy, [Caraballo, Luis] Univ Cartagena, Inst Immunol Res, Campus Zaragocilla, Cartagena, Colombia, [Caraballo, Luis] Fdn Dev Med & Biol Sci Fundemeb, Cartagena, Colombia, [Cardona, Victoria] Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain, [Cardona, Victoria] ARADyAL Res Network, Barcelona, Spain, [Maria Carriazo, Ana] Reg Minist Hlth Andalusia, Seville, Spain, [Cash, Eugene] Nova Southeastern Univ, Coll Psychol, Ft Lauderdale, FL 33314 USA, [Cash, Eugene] Sch Related Psychol Assessments & Clin Intervent, Ft Lauderdale, FL USA, [Cecchi, Lorenzo] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy, [Schunemann, Holger J.] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy, [Chu, Derek K.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Dept Med, Div Immunol & Allergy, Hamilton, ON, Canada, [Colgan, Elaine] Dept Hlth Social Serv & Publ Safety, Belfast, Antrim, North Ireland, [Costa, Elisio] Univ Porto, UCIBIO, Fac Pharm, REQUIMTE, Porto, Portugal, [Costa, Elisio] Univ Porto, AgeUPNetWork, Competence Ctr Act & Hlth Ageing, Porto, Portugal, [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil, [Cruz, Alvaro A.] WHO GARD Execut Comm, Salvador, BA, Brazil, [Czarlewski, Wienczyslawa] Med Consulting Czarlewski, Levallois Perret, France, [Durham, Stephen] Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England, [Ebisawa, Motohiro] Natl Hosp Org, Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan, [Erhola, Marina] Natl Inst Hlth & Welf, Helsinki, Finland, [Fauquert, Jean-Luc] CHU Clermont Ferrand, Hop Estaing, Pole Pediat, Unit Allergol Enfant, Clermont Ferrand, France, [Fokkens, Wytske J.] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, AMC, Amsterdam, Netherlands, [Fonseca, Joao A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst, Fac Med, CINTESIS, Porto, Portugal, [Fonseca, Joao A.] Medida Lda, Porto, Portugal, [Guldemond, Nick] Erasmus Univ, Inst Hlth Policy & Management iBMG, Rotterdam, Netherlands, [Iinuma, Tomohisa] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan, [Okamoto, Yoshitaka] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan, [Illario, Maddalena] Campania Reg, Div Hlth Innovat, Naples, Italy, [Illario, Maddalena] Federico II Univ Hosp Naples, R&D, Naples, Italy, [Illario, Maddalena] Federico II Univ Hosp Naples, DISMET, Naples, Italy, [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany, [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland, [Kvedariene, Violeta] Vilnius Univ, Fac Med, Dept Pathol, Inst Biomed Sci, Vilnius, Lithuania, [Kvedariene, Violeta] Fac Med, Inst Clin Med, Clin Chest Dis & Allergol, Vilnius, Lithuania, [Larenas-Linneman, Desiree] Med Sur Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico, [Laune, Daniel] KYomed INNOV, Montpellier, France, [Le, Lan T. T.] Univ Med & Pharm, Hochiminh City, Vietnam, [Lourenco, Olga] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal, [Lourenco, Olga] Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal, [Malva, Joao O.] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal, [Malva, Joao O.] Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal, [Menditto, Enrica] Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy, [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain, [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Spain, [Mullol, Joaquim] Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain, [Munter, Lars] Danish Comm Hlth Educ, Copenhagen East, Denmark, [Papadopoulos, Nikos G.] Univ Manchester, Royal Manchester Childrens Hosp, Div Infect Immun & Resp Med, Manchester, Lancs, England, [Papadopoulos, Nikos G.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Allergy Dept, Pediat Clin 2, Athens, Greece, [Perala, Maritta] Univ Oulu, Fac Med, Oulu, Finland, [Pfaar, Oliver] Phillipps Univ Marburg, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany, [Phillips, Abigail] Welsh Govt, Dept Hlth & Social Serv, Cardiff, S Glam, Wales, [Phillips, Jim] Ctr Empowering Patients & Communities, Dublin, Ireland, [Pinnock, Hilary] Univ Edinburgh, Asthma UK Ctr Appl Res, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland, [Quinones-Delgado, Pablo] Agcy Social Serv & Dependency, Reg Govt Equal Social Policies & Conciliat Andalu, Seville, Spain, [Rolland, Christine] Assoc Asthme & Allergie, Paris, France, [Rodts, Ulysse] KanopyMed, Paris, France, [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland, [Sanchez-Borges, Mario] Ctr Medicodocente La Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela, [Shamji, Mohamed] Imperial Coll London, Immunomodulat & Tolerance Grp, London, England, [Shamji, Mohamed] Imperial Coll London, Allergy & Clin Immunol, London, England, [Somekh, David] EHFF, Dromahair, Ireland, [Togias, Alkis] NIAID, DAIT, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA, [Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland, [Toppila-Salmi, Sanna] Univ Helsinki, Helsinki, Finland, [Tsiligianni, Ioanna] Univ Crete, Fac Med, Dept Social Med, Hlth Planning Unit, Iraklion, Greece, [Tsiligianni, Ioanna] Int Primary Care Resp Grp, Aberdeen, Scotland, [Williams, Sian] Int Primary Care Resp Grp, Aberdeen, Scotland, [Usmani, Omar] Royal Brompton Hosp, Airways Dis Sect, London, England, [Walker, Samantha] Asthma UK, London, England, [Wallace, Dana] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA, [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Fac Med, Vilnius, Lithuania, [Valiulis, Arunas] Inst Hlth Sci, Vilnius, Lithuania, [Van der Kleij, Rianne] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands, [Ventura, Maria Teresa] Univ Bari, Unit Geriatr Immunoallergol, Med Sch, Bari, Italy, [Yorgancioglu, Arzu] Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey, [Zuberbier, Torsten] Univ Med Berlin, Berlin, Germany, [Zuberbier, Torsten] Free Univ Berlin, Berlin, Germany, [Zuberbier, Torsten] Humboldt Uniersitat Berlin, Berlin, Germany, [Zuberbier, Torsten] GA2LEN, Berlin, Germany, Mylan, GSK, ALK, Novartis, Sanofi, Stallergenes-Greer, Uriach, Health Services Management & Organisation (HSMO), Bousquet, J., Pham-Thi, N., Bedbrook, A., Agache, I., Annesi-Maesano, I., Ansotegui, I., Anto, J. M., Bachert, C., Benveniste, S., Bewick, M., Billo, N., Bosnic-Anticevich, S., Bosse, I., Brusselle, G., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Carriazo, A. M., Cash, E., Cecchi, L., Chu, D. K., Colgan, E., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S., Ebisawa, M., Erhola, M., Fauquert, J. -L., Fokkens, W. J., Fonseca, J. A., Guldemond, N., Iinuma, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linneman, D., Laune, D., Le, L. T. T., Lourenco, O., Malva, J. O., Marien, G., Menditto, E., Mullol, J., Munter, L., Okamoto, Y., Onorato, G. L., Papadopoulos, N. G., Perala, M., Pfaar, O., Phillips, A., Phillips, J., Pinnock, H., Portejoie, F., Quinones-Delgado, P., Rolland, C., Rodts, U., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Shamji, M., Somekh, D., Togias, A., Toppila-Salmi, S., Tsiligianni, I., Usmani, O., Walker, S., Wallace, D., Valiulis, A., Van der Kleij, R., Ventura, M. T., Williams, S., Yorgancioglu, A., Zuberbier, T., and uBibliorum
Subjects: 0301 basic medicine, Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, Aria, Allergic rhinitis - Asthma - Multimorbidity, Health literacy, Chronic respiratory-diseases, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Health care, medicine, Self-management, Global alliance, Intensive care medicine, mHealth, Asthma, Newsletter of GARD Section, business.industry, Environmental exposure, medicine.disease, 3. Good health, Integrated care, 030104 developmental biology, Impact, 030228 respiratory system, 13. Climate action, business
Abstract: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative (2), and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (3), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs—centred around the patient with rhinitis and using mHealth monitoring of environmental exposure. An expert meeting took place at the Pasteur Institute in Paris, December 3, 2018. The aim was to discuss nextgeneration care pathways following an ongoing political agenda (4,5): (I) patient participation, health literacy and self-care through technology-assisted “patient activation”; (II) implementation of care pathways by pharmacists and (III) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) assessed by mobile technology. The present document reviews the workshop report and follows on from Part 1.
Published: 2019

43. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

Author: Piotr Kuna, J. C. Ivancevich, Dana Wallace, Alvaro A. Cruz, Igor Kaidashev, Louis-Philippe Boulet, Anna Bedbrook, Marek L. Kowalski, Ioana Agache, Hae-Sim Park, Gregoire Mercier, Mario Sánchez-Borges, Karl-Christian Bergmann, Tomohisa Iinuma, Peter Hellings, Graham Roberts, Erkka Valovirta, Antonella Muraro, Robyn E O'Hehir, Oliver Pfaar, Luis Caraballo, Mohamed H. Shamji, Torsten Zuberbier, Guy Brusselle, Nicolas Roche, Dermot Ryan, Holger J. Schünemann, Ignacio J. Ansotegui, Erik Melén, V. Cardona, Wienczyslawa Czarlewski, Mike Bewick, Ana-Maria Todo Bom, Susan Waserman, Sinthia Bosnic-Anticevich, Ludger Klimek, Isabelle Bosse, Sanna Toppila-Salmi, Giovanni Passalacqua, Daniel Laune, Lan Le, Despo Ierodiakonou, Gert Marien, Derek K. Chu, Akdis Togias, M. T. Ventura, Marek Jutel, Désirée Larenas-Linnemann, João Fonseca, Elísio Costa, Motohiro Ebisawa, Mark S. Dykewicz, Roy Gerth van Wijk, Musa Khaitov, Pedro Carreiro-Martins, Ioana Tsiligianni, Ettore Novellino, Wytske Fokkens, Nelson Rosario, Thomas B. Casale, Philippe Bonniaud, Bolesław Samoliński, Omer Kalayci, Olga Lourenço, Yoshitaka Okamoto, Moises A. Calderon, Stefania La Grutta, Gennaro D'Amato, Glenis Scadding, Bilun Gemicioglu, Petr Panzner, Philippe Devillier, Ralph Mosgues, Susanne Halken, Susanne Lau, Violeta Kvedariene, Aziz Sheikh, Samantha Walker, Marylin Valentin-Rostan, Martina Erhola, Nhan Pham-Thi, Christine Rolland, H. Neffen, Jean Bousquet, Jean-François Fontaine, Jacques Bouchard, Jean-Louis Fauquert, Arunas Valiulis, Claus Bachert, Lorenzo Cecchi, Jorg Kleine Tebbe, Walter Canonica, David Price, Tari Haahtela, Ken Ohta, Philipp Lieberman, Leyla Namazova, Karin C. Lødrup Carlsen, Joaquim Mullol, Enrica Menditto, Arzu Yorgancioglu, Jan Brozek, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Humboldt-Universität zu Berlin, McMaster University [Hamilton, Ontario], National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Upper Airways Research Laboratory, Universiteit Gent = Ghent University [Belgium] (UGENT), National Institute for Health and Welfare [Helsinki], University Hospitals Leuven [Leuven], VU University Medical Center [Amsterdam], Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Philipps Universität Marburg, Nova Southeastern University (NSU), Hospital Quirónsalud Bizkaia [Bilbao], Transilvania University of Brasov, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], iQ4U consultants Ltd, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Allergist [La Rochelle], Laval University Medical center, Université Laval [Québec] (ULaval), Quebec Heart and Lung Institute, Ghent University Hospital, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Humanitas University [Milan] (Hunimed), Institute for Immunological Research (University of Cartagena), Vall d'Hebron University Hospital [Barcelona], RETIC ARADyAL, University of South Florida [Tampa] (USF), SOS Allergology and Clinical Immunology, Unidade de Ciencias Biomoleculares Aplicadas (UCIBIO), Requimte, Departamento de Química (DQ), Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto, ProAR – Nucleo de Excelencia em Asma, Universidade Federal da Bahia (UFBA), Medical Consulting Czarlewski, 'Federico II' University of Naples Medical School, Laboratoire de Pharmacologie Respiratoire UPRES EA220, UPRES EA 220, Pôle des maladies respiratoires, Hôpital Foch, Washington University School of Medecine [Saint Louis, MO], Sagamihara National Hospital, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Department of Otorhinolaryngology [Amsterdam], Academic Medical Centre [Amsterdam], University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Allergist [Reims], Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Skin and allergy hospital [Helsinki, Finland], Odense University Hospital [Odense, Denmark], University General Hospital of Heraklion, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Wroclaw Medical University [Wrocław, Pologne], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], Hacettepe University School of Medicine, DRK Kliniken Berlin, Westend, Medical University of Łódź (MUL), Barlicki University Hospital, Vilnius University [Vilnius], Institute of Biomedicine and Molecular Immunology (IBIM), Hospital Medica Sur [Mexico City, Mexico], KYomed INNOV [Montpellier], Ho Chi Minh City University of Medicine, The University of Tennessee Health Science Center [Memphis] (UTHSC), Oslo University Hospital [Oslo], University of Beira Interior [Portugal] (UBI), Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Sachs’ Children and Youth Hospital [Stockholm, Sweden], Karolinska Institutet [Stockholm], Center for Allergy and Immunology and Respiratory Diseases, Département d'Information Médicale [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University Hospital of Cologne [Cologne], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), University Hospital of Padua, Pirogov Russian National Research Medical University [Moscow, Russia], Monash University [Melbourne], Tokyo National Hospital, Ajou University, Charles University [Prague] (CU), Ospedale Policlinico San Martino [Genoa], Centre Médical de l'Institut Pasteur, Institut Pasteur [Paris], Observational and Pragmatic Research Institute, Singapore, Singapore, The David Hide Asthma and Allergy Research Centre, St Mary's Hospital-University Hospital Southampton NHS Foundation Trust, Département des maladies respiratoires [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Association Asthme et Allergies, Universidade Federal do Parana [Curitiba] (UFPR), Universidade Federal do Paraná (UFPR), University of Edinburgh, Medical University of Warsaw - Poland, Centro Médico Docente La Trinidad, The Royal National TNE Hospital, University College of London [London] (UCL), Imperial College London, Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Coimbra [Portugal] (UC), University of Helsinki, University of Crete [Heraklion] (UOC), Allergist, University of Turku, Terveystalo Pulssi, University of Bari Aldo Moro (UNIBA), Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, (MRC), Guy's Hospital [London], Manisa Celal Bayar University, uBibliorum, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Humboldt University Of Berlin, Universiteit Gent = Ghent University (UGENT), Philipps Universität Marburg = Philipps University of Marburg, Universidade do Porto = University of Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto = University of Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Washington University School of Medicine [Saint Louis, MO], Sagamihara National Hospital [Kanagawa, Japan], Universidade do Porto = University of Porto, Wrocław Medical University, Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Pirogov Russian National Research Medical University, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Internal Medicine, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade do Porto-Departamento de Química (DQ), and CCSD, Accord Elsevier
Subjects: MESH: Asthma, Allergy, [INFO.INFO-DS] Computer Science [cs]/Data Structures and Algorithms [cs.DS], Disease, Allergic Rhinitis and Its Impact on Asthma, medicine.disease_cause, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Allergic rhinitis, Grading of Recommendations Assessment, law.invention, 0302 clinical medicine, Allergen, Randomized controlled trial, MESH: Practice Guidelines as Topic, law, HDE ALER, HEALTH LITERACY, Immunology and Allergy, 030212 general & internal medicine, guidelines, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, MASK-RHINITIS, mHealth, PLACEBO, LORATADINE, MOBILE TECHNOLOGY, 3. Good health, Evidence-Based Practice, Practice Guidelines as Topic, MESH: Rhinitis, Allergic, AZELASTINE NASAL SPRAY, Life Sciences & Biomedicine, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, Algorithms, medicine.medical_specialty, Evidence-based practice, Visual analogue scale, [INFO.INFO-DS]Computer Science [cs]/Data Structures and Algorithms [cs.DS], Immunology, MESH: Algorithms, MACVIA-ARIA, 03 medical and health sciences, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, Pharmacotherapy, medicine, Humans, QUALITY, Development and Evaluation, real-world evidence, Intensive care medicine, Asthma, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Humans, Science & Technology, business.industry, MESH: Evidence-Based Practice, medicine.disease, EFFICACY, Rhinitis, Allergic, 030228 respiratory system, ONSET, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, business
Abstract: The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:145 issue:1 pages:70-+ ispartof: location:United States status: published
Published: 2019

44. 2019 ARIA Care pathways for allergen immunotherapy

Author: Dana Wallace, Karin C. Lødrup Carlsen, M. T. Ventura, Igor Kaidashev, Stephen R. Durham, Motohiro Ebisawa, Oliver Pfaar, Hae-Sim Park, Daniel Laune, Wytske Fokkens, Antonella Muraro, Moises A. Calderon, Torsten Zuberbier, Mohamed H. Shamji, Mark S. Dykewicz, Roy Gerth van Wijk, Josep M. Antó, Samantha Walker, Petr Panzner, Giorgio Walter Canonica, Nelson Rosario, Juan Carlos Ivancevich, Holger J. Schünemann, Susanne Halken, Lorenzo Cecchi, Sinthia Bosnic-Anticevich, Violeta Kvedariene, Stefania La Grutta, João Fonseca, Marek L Kowalski, Tari Haahtela, Aziz Sheikh, Montserrat Fernandez-Rivas, Nhan Pham-Thi, Isabelle Bosse, Jean Bousquet, Lan Le, Despo Ierodiakonou, Tomohisa Iinuma, Lars Jacobsen, Christine Rolland, Gert Marien, Wienczyslawa Czarlewski, Glenis Scadding, Ioana Agache, Bolesław Samoliński, Olga Lourenço, Ludger Klimek, Yoshitaka Okamoto, Ulrich Wahn, Joaquim Mullol, Erkka Valovirta, Luigi Caraballo, Sanna Toppila-Salmi, Ioanna Tsiligianni, Derek K. Chu, Ruby Pawankar, Jean Luc Fauquert, Musa Khaitov, Jorg Kleine Tebbe, Jean-François Fontaine, Victoria Cardona, Désirée Larenas-Linemann, Thomas B. Casale, Omer Kalayci, Alvaro A. Cruz, Arunas Valiulis, Anna Bedbrook, Susanne Lau, Alkis Togias, H.-J. Malling, Claus Bachert, Dermot Ryan, Elísio Costa, Giovanni Passalacqua, Ignacio J. Ansotegui, Ana Todo Bom, Marek Jutel, Enrica Menditto, Piotr Kuna, Nikolaos G. Papadopoulos, Gregoire Mercier, Mario Sánchez-Borges, Karl-Christian Bergmann, Susan Waserman, Gunter J. Sturm, Maryline Valentin-Rostan, Arzu Yorgancioglu, Giovanni Battista Pajno, Jan Brozek, George Du Toit, Robyn E O'Hehir, Peter Hellings, Graham Roberts, uBibliorum, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Center for Rhinology and Allergology, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Allergy and Immunology, Hospital Quiròn Bizkaia Erandio, UPC Research Laboratories, Allergy Department, University of Crete [Heraklion] (UOC), Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Universitat Pompeu Fabra [Barcelona] (UPF), Ghent University Hospital, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Dermatology and Allergy [Berlin, Allemagne], Comprehensive Allergy Center [Berlin, Allemagne], Berlin Institute of Health (BIH)-Berlin Institute of Health (BIH), The University of Sydney, Woolcock Institute of Medical Research [Sydney], CHU Montpellier, Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Section of Allergy and Clinical Immunology [London, UK], Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Institute for Immunological Research (University of Cartagena), University of Cartagena, Allergy Section, Department of Internal Medicine, Vall d'Hebron University Hospital [Barcelona], Division of Allergy and Immunology, Department of Medicine, Creighton University, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), Universidade Federal da Bahia (UFBA), UCB Pharma, Colombes, Section of Allergy and Clinical Immunology, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], King‘s College London, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Department of Allergology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Helsinki University Hospital, Odense University Hospital, University Hospitals Leuven [Leuven], Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Research Centre for Prevention and Health (RCPH), Department of Public Health [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Capital Region of Denmark, Department of Clinical Immunology, Wroclaw Medical University, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Laboratory of Molecular Immunology [Moscow, Russian Federation] (National Research Center), Institute of Immunology [Moscow, Russian Federation]-Federal Medicobiological Agency [Moscow, Russian Federation], Hacettepe University = Hacettepe Üniversitesi, Allergy & Asthma Center Westend, Outpatient Clinic Hanf, Department of Immunology, Rheumatology and Allergy, Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], CNR-IBIM : National Research Council-Institute of Biomedicine and Molecular Immunology, Department of Pediatric Pneumology and Immunology, Ho Chi Minh City University of Technology (HCMUT), University of Oslo (UiO), Faculty of Health Sciences and CICS-UB (Health Sciences Research Centre), 'Federico II' University of Naples Medical School, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Food Allergy Referral Centre Veneto Region [Padua, Italy], Universita degli Studi di Padova, Monash University [Melbourne], Department of Otorhinolaryngology, Department of Pediatrics, Allergy Unit, University of Messina, Ajou University School of Medicine, Department of Allergology and Clinical Immunology, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Allergy and Respiratory Diseases, University of Genoa (UNIGE), Saint Mary's Hospital [London], St Mary's Hospital [London], Department of Pediatrics, Nippon Medical School, Pediatrics, Universidade Federal do Paraná (UFPR), Medical Centre, Woodbrook Medical Centre, Medical University of Warsaw - Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Medico-Docente La Trinidad, The Royal National Throat, Nose and Ear Hospital, Imperial College London, Centre for Population Health Sciences, University of Edinburgh, Medical University Graz, University of Coimbra [Portugal] (UC), Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Università degli studi di Bari Aldo Moro (UNIBA), Department for Pediatric Pneumology and Immunology, Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, (MRC), Guy's Hospital [London], Nova Southeastern University (NSU), Department of Pulmonology, Manisa Celal Bayar University, Department of Dermatology, Medical School-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Association Asthme et Allergie, Internal Medicine, Bousquet, J., Pfaar, O., Togias, A., Schunemann, H. J., Ansotegui, I., Papadopoulos, N. G., Tsiligianni, I., Agache, I., Anto, J. M., Bachert, C., Bedbrook, A., Bergmann, K. -C., Bosnic-Anticevich, S., Bosse, I., Brozek, J., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Casale, T., Cecchi, L., Chu, D., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S. R., Du Toit, G., Dykewicz, M., Ebisawa, M., Fauquert, J. L., Fernandez-Rivas, M., Fokkens, W. J., Fonseca, J., Fontaine, J. -F., Gerth van Wijk, R., Haahtela, T., Halken, S., Hellings, P. W., Ierodiakonou, D., Iinuma, T., Ivancevich, J. C., Jacobsen, L., Jutel, M., Kaidashev, I., Khaitov, M., Kalayci, O., Kleine Tebbe, J., Klimek, L., Kowalski, M. L., Kuna, P., Kvedariene, V., La Grutta, S., Larenas-Linemann, D., Lau, S., Laune, D., Le, L., Lodrup Carlsen, K., Lourenco, O., Malling, H. -J., Marien, G., Menditto, E., Mercier, G., Mullol, J., Muraro, A., O'Hehir, R., Okamoto, Y., Pajno, G. B., Park, H. -S., Panzner, P., Passalacqua, G., Pham-Thi, N., Roberts, G., Pawankar, R., Rolland, C., Rosario, N., Ryan, D., Samolinski, B., Sanchez-Borges, M., Scadding, G., Shamji, M. H., Sheikh, A., Sturm, G. J., Todo Bom, A., Toppila-Salmi, S., Valentin-Rostan, M., Valiulis, A., Valovirta, E., Ventura, M. -T., Wahn, U., Walker, S., CORBO UGULINO, Wallace, Waserman, S., Yorgancioglu, A., Zuberbier, T., Hospital Quirónsalud Bizkaia [Bilbao], Sagamihara National Hospital [Kanagawa, Japan], Universidade do Porto = University of Porto, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Capital Region of Denmark, Wrocław Medical University, Università degli Studi di Padova = University of Padua (Unipd), Charles University [Prague] (CU)-Medical Faculty in Pilsen, Università degli studi di Genova = University of Genoa (UniGe), Centro Médico Docente La Trinidad, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), and Hibade, Monique
Subjects: Cost effectiveness, [SDV]Life Sciences [q-bio], Cost-Benefit Analysis, Comorbidity, medicine.disease_cause, 0302 clinical medicine, Allergen, Cost of Illness, Immunology and Allergy, Medicine, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Precision Medicine, mHealth, Children, media_common, Allergen immunotherapy, Rhinitis, Disease Management, 3. Good health, [SDV] Life Sciences [q-bio], rhiniti, Treatment Outcome, Practice Guidelines as Topic, Critical Pathways, [SDV.IMM]Life Sciences [q-bio]/Immunology, Disease Susceptibility, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Attitude of Health Personnel, Immunology, Clinical Decision-Making, 03 medical and health sciences, Pharmacotherapy, rhinitis, stratification, children, media_common.cataloged_instance, Animals, Humans, European union, Intensive care medicine, allergen immunotherapy, asthma, children, mHealth, rhinitis, stratification, Asthma, business.industry, Allergens, asthma, medicine.disease, Rhinitis, Allergic, Review article, 030228 respiratory system, Desensitization, Immunologic, allergen immunotherapy, Stratification, business, Biomarkers
Abstract: Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.
Published: 2019

45. The influence of tonsillectomy on allergic diseases in pediatric patients

Author: Yoshitaka Okamoto, Atsuko Nakano, Akiko Yamaide, Daiju Sakurai, Tomohisa Iinuma, Minako Tomiita, Urara Funakoshi, Akira Hoshioka, Syuji Yonekura, and Yukiko Arimoto
Subjects: Allergy, medicine.medical_specialty, Rhinitis, Allergic, Perennial, medicine.medical_treatment, Stimulation, medicine.disease_cause, Immunoglobulin E, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Allergen, 030225 pediatrics, Internal medicine, Hypersensitivity, Humans, Medicine, Antigens, Dermatophagoides, Child, 030223 otorhinolaryngology, Tonsillectomy, Asthma, biology, business.industry, General Medicine, Allergens, Airway obstruction, medicine.disease, Otorhinolaryngology, Pediatrics, Perinatology and Child Health, biology.protein, business, Airway
Abstract: Background The influence of tonsillectomy on allergic airway diseases is not well known. Objectives In the present study, the influence of tonsillectomy on perennial allergic rhinitis (PAR) and bronchial asthma (BA) among pediatric subjects was prospectively investigated. Methods The tonsillectomy (surgery group) and the age-matched non-surgical subjects (control group) were examined and followed prospectively. In addition, immunological analysis was conducted. Results After in vitro allergen stimulation, the production of a small number of allergen-specific Th2 cells was induced in the tonsillar cells, even in sensitized subjects. Flow cytometry analysis detected more effector regulatory T cells (Tregs) in the tonsils than in peripheral blood. Clinically, after surgery, the PAR and BA symptoms improved in the surgery group but not in the control group. The total IgE in the surgery group was significantly lower than in the control group; after surgery, IgE levels slightly increased but remained lower. The postoperative Dermatophagoides farina (Der f)-specific IgE level increased in the sensitized subjects but not in the non-sensitized subjects. Conclusion Tonsillectomy did not improve the underlying mechanisms of the allergy, however the decreased risk of infection and upper airway obstruction could lead to improved symptoms of allergic airway diseases.
Published: 2021

46. Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success

Author: S Suzuki, Yuki Morimoto, Tomohisa Iinuma, Yoshitaka Okamoto, Toshioki Sakurai, Shinya Kaneko, Yusuke Okuma, Shuji Yonekura, Tomoyuki Arai, D. Sakurai, and Yukiyoshi Mita
Subjects: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Cryptomeria, medicine.medical_treatment, Immunoglobulins, Placebo, Gastroenterology, law.invention, 03 medical and health sciences, Th2 Cells, Double-Blind Method, Randomized controlled trial, law, Internal medicine, otorhinolaryngologic diseases, medicine, Humans, Sublingual immunotherapy, Lymphocyte Count, Sublingual Immunotherapy, biology, Plant Extracts, business.industry, Rhinitis, Allergic, Seasonal, FOXP3, Forkhead Transcription Factors, Immunotherapy, General Medicine, Middle Aged, Th1 Cells, Slit, Interleukin-10, Interleukin 10, Treatment Outcome, 030104 developmental biology, Otorhinolaryngology, Immunology, biology.protein, Female, sense organs, Antibody, business, Biomarkers
Abstract: Background: Biomarkers that enable objective evaluation of the clinical effects of immunotherapy for allergic rhinitis have yet to be identified. Methods: This study included 40 patients who were enrolled in a large randomized, double-blind, placebo-controlled, multicenter study examining the efficacy of sublingual immunotherapy (SLIT) using Japanese cedar (JC) pollen extract during two consecutive pollen seasons from 2010 to 2012. Based on changes in total nasal symptom medication score, patients in the SLIT and placebo groups were subdivided into two subgroups: good responders and poor responders. The levels of JC pollen-specific IL-10+Foxp3+ cells and specific Th2 cytokine-producing cells were measured and the association with the efficacy of SLIT was analysed. Results: The total nasal symptom medication score was significantly lower in the SLIT group compared with the placebo group. The number of JC pollen-specific Th2 cytokine-producing cells increased during the pollen season in the placebo group and in poor responders in the SLIT group; however, the increases were inhibited in the good responders in the SLIT group. The number of JC pollen-specific IL-10+Foxp3+ cells increased only in these good responders. Conclusions: Changes in levels of allergen-specific Th2 cytokine-producing cells and IL-10+Foxp3+ cells could be objective biomarkers for SLIT.
Published: 2016

47. Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber

Author: Yusuke Okuma, Yuji Ohki, Daiju Sakurai, Toshioki Sakurai, Syuji Yonekura, Sawako Hamasaki, Tomohisa Iinuma, Heizaburo Yamamoto, and Yoshitaka Okamoto
Subjects: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, genetic structures, Cryptomeria, Immunology, Tryptase, medicine.disease_cause, Severity of Illness Index, Mediator release, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pollen, otorhinolaryngologic diseases, Humans, Immunology and Allergy, Medicine, Nose, biology, business.industry, Rhinitis, Allergic, Seasonal, Cedar pollinosis, Environmental Exposure, Allergens, Immunoglobulin E, Middle Aged, Nasal Lavage Fluid, Nasal Mucosa, stomatognathic diseases, Phenotype, 030104 developmental biology, medicine.anatomical_structure, 030228 respiratory system, chemistry, Anesthesia, Exhaled nitric oxide, biology.protein, Cytokines, Female, Inflammation Mediators, business, Biomarkers, Histamine, Nasal symptoms
Abstract: Background Immediate- and late-phase reactions are associated with nasal symptoms of patients with allergic rhinitis. Objective To examine the symptoms and mediators released after continuous allergen exposure in an environmental challenge chamber (ECC). Methods Fifteen patients with Japanese cedar pollinosis were enrolled in this study and continuously exposed to cedar pollen at a concentration of 8,000 grains/m 3 for 3 hours in an ECC. Nasal function tests were performed, and nasal secretions were collected before pollen exposure (0 hour), immediately after exiting the ECC (3 hours), and 6 hours after exiting the ECC (9 hours). Symptom scores were recorded every 30 minutes in the ECC and every 3 hours after exiting the ECC. The frequency of sneezing and nose blowing also was monitored. Results The severity of symptoms in the ECC peaked approximately 2 hours after the beginning of pollen exposure and continued more than 6 hours after leaving the ECC. Concentrations of histamine, tryptase, interleukins 5, 3, 33, and 31, and substance P increased over time, whereas that of nasal fractional exhaled nitric oxide decreased. Conclusion Various mediators are released during continuous allergen exposure, which subsequently induce persistent nasal symptoms. Effective treatment is required to control the intense inflammation observed after allergen exposure.
Published: 2016

48. Two cases of invasive fungal sinusitis showing orbital apex syndrome

Author: Syuji Yonekura, Yoshitaka Okamoto, Kazuki Yamasaki, Hideaki Chazono, Hiroko Nakamura, Keiichi Koshizuka, Tomohisa Iinuma, and Toyoyuki Hanazawa
Subjects: Pathology, medicine.medical_specialty, Invasive fungal sinusitis, business.industry, Medicine, business, Orbital apex
Published: 2016

49. Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Author: Yoshitaka Okamoto, Tomoyuki Arai, Fumie Ihara, Toyoyuki Hanazawa, Toshioki Sakurai, Daiju Sakurai, Tomohisa Iinuma, Yusuke Okuma, Satoshi Suzuki, Emi Fukuda-Kawaguchi, Syuji Yonekura, and Yasuyuki Ishii
Subjects: lcsh:Immunologic diseases. Allergy, Male, Allergen immunotherapy, Ovalbumin, medicine.medical_treatment, Galactosylceramides, Immunoglobulin E, medicine.disease_cause, Sublingual administration, Allergen, Th2 Cells, Adjuvants, Immunologic, Immunology and Allergy, Medicine, Animals, Lymph node, Sublingual Immunotherapy, biology, business.industry, General Medicine, respiratory system, Allergens, Natural killer T cell, Rhinitis, Allergic, Mice, Mutant Strains, Mice, Inbred C57BL, Disease Models, Animal, medicine.anatomical_structure, Cytokine, Treatment Outcome, Immunoglobulin G, Immunology, Liposomes, biology.protein, Cytokines, Th17 Cells, lcsh:RC581-607, business, Adjuvant
Abstract: Background: Sublingual immunotherapy (SLIT) is an established efficacious approach for the treatment of allergic rhinitis (AR). However, SLIT requires a long administration period to establish stable and adequate responses. This study investigated the efficacy of the sublingual administration of an allergen with liposomes enclosing α-GalCer (α-GC-liposome) as a potential adjuvant in mice with AR. Methods: Mice with AR induced by OVA received the sublingual administration of OVA, α-GC-liposomes, or OVA plus α-GC-liposomes for 7 days. After nasal re-challenge with OVA, nasal symptoms were evaluated. The serum levels of OVA-specific Ig, the cytokine production of CD4+ T cells in the cultures of cervical lymph node (CLN) cells, and the gene expression of CLNs were analyzed. Results: Although IL-4, IL-5 and IL-13 production from CD4+ T cells in CLN cells was significantly inhibited by the sublingual administration of OVA alone in mice with AR induced by OVA, their nasal symptoms were not significantly diminished. However, the combined sublingual administration of α-GC-liposomes and OVA completely suppressed nasal symptoms, downregulated Th2 and Th17 type cytokine production in CD4+ T cells as well as Th2 and Th17 gene expressions, and upregulated Th1 type cytokine production as well as Th1 gene expressions in CLN cells. Additionally, the serum levels of specific IgG2a were promoted, and specific IgE and IgG1 were inhibited. Conclusions: Our findings suggest that the sublingual administration of an allergen with α-GC-liposomes as an adjuvant might increase the therapeutic efficacy and effectiveness of this treatment method. Keywords: Allergic, Liposome, Mice, Natural killer T-Cells, Rhinitis
Published: 2018

50. Memory T cell function in the onset of allergic Rhinitis and effect of Immunotherapy

Author: Tomohisa Iinuma
Published: 2018

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

76 results on '"Tomohisa Iinuma"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources